第三国集团研修 事前調查団 報告書

一黄熱・ポリオ実験室内診断技術ー

1996年12月



国際協力事業団研修事業部

研 三 JR

第三国集团研修 事前調查团 報告書

一黄熱・ポリオ実験室内診断技術ー

1996年12月

国際協力事業団研 修 事 業 部

1139501 (9)

第三国研修とは、わが国の技術協力によって開発途上国に移転された技術を活用して、 当該国の実施機関が、社会的、文化的、言語的に共通の基盤を持つ周辺の開発途上国から の研修員を受け入れ、わが国で実施することに比較して、より現地事情に適合した技術、 知識の移転を図り、もって、開発途上国間協力の推進に寄与するとともに、将来的には、 実施機関が独自に研修員受け入れ事業を展開することが可能となるように組織育成を行う こと等を目的として実施されるわが国研修員受け入れ事業の一形態である。第三国研修は 、昭和49年度にタイ国コラート養蚕訓練センターにおいて最初のコースが開設されて以 来、要請、予算ともに増加の一途を辿り、平成8年度には全世界で100件を越えるコー スの実施が計画されるに至っている。特に近年では、途上国間の協力、いわゆる「南々協 力」の最も典型的かつ効果的な方法として、一段と脚光を浴びている事業でもある。

アフリカにおける第三国研修は、わが国の過去の技術協力の成果をベースとする条件から、ニーズに比較して研修コースの新設が制限されている現状にあり、平成8年度現在でケニアで3コース、象牙海岸で1コースの合計4コースを数えるのみである。

このような中で、ガーナ大学医学部付属野口記念医学研究所を実施機関とする本件第三国研修は、平成3年度から平成7年度にかけて成功裡に実施された「ワクチン力価試験及びポリオ関連診断技術」コースの次期コースとしてガーナ政府から協力の要請がなされたものである。前回のコースは、昭和40年代後半から継続的に実施されてきたわが国技術協力の成果を基礎に、また、世界保健機構(WHO)が推進する「ポリオ撲滅計画」の流れに沿って、ガーナ政府とわが国政府及び国際機関であるWHOの三者協力による、いわゆるマルチ・バイ技術協力の先駆けとして目覚ましい成果をあげた。

本件調査団は、厚生省の協力を得て平成8年8月22日から9月2日までの間、ガーナにおける現地調査及び協力者となるWHO本部での協議を行った。本報告書はその結果を取り纏めたものである。

本件調査の実施にあたり、並々ならぬ協力を賜った、厚生省、国立予防衛生研究所、在ガーナ日本大使館、その他の関連機関に対して深甚なる謝意を表するものである。

平成8年12月

国際協力事業団 研修事業部長 森本 勝 本件第三国研修は、平成3年度から平成7年度にわたり実施された「ワクチンカ価試験及びポリオ関連診断技術」コースが、実施機関であるガーナ大学医学部付属野口記念医学研究所、世界保健機構(WHO)及び日本政府の三者によるマルチ・バイ協力の成功を踏まえ、その第二フェーズとして要請されたものである。

本件第三国研修で中心的な課題となる黄熱病は、近年赤道をはさむアフリカ各国において流行の兆がみえる熱帯性感染症であり、WHOも予防接種の推進に注目し始めている重要疾患である。

本件第三国研修の実施機関となる野口研は、長年に亙るわが国技術協力により試験・研究の基盤が整備されているばかりか、WHOの指定するアフリカ地域では唯一の感染症研究所でもあり、第三国研修の実施について十分な実施能力を有することが確認された。

本件第三国研修は、黄熱病診断のための必要な施設、機材及び検査体制を有するアフリカ8か国を対象として平成8年度より3年に亙り実施することが合意された。

一般的にわが国に知見、情報の不足しているアフリカにおける人造り事業においては、WHOを始めとする国際機関との協調は、わが国技術協力の枠を広げる上で極めて有効な方法であると考えられる。その意味で本件第三国研修の帰趙は今後のマルチ・バイ技術協力の将来を占う重要な試金石になるものと思われる。

(1) WHO本部での協議



後列:左から土井博士、有田団員、リー局長、高橋団長、ザフラン博士、チェイネ博士、

前列:左からハル博士、細川団員

(2) 野口研での協議



正面左がエンクルマ所長、右が高橋団長

序	文	
要	約	
写	真	ላ -:
1 -	- 1 - 2	が調査団の派遣 調査団派遣の経緯と目的
2 2 - 2 -	- I	情の背景 周辺国の研修ニーズ
3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 - 3 -	- 1 - 2 - 3 - 4	資結果の概要 (第三国集団研修基本計画)11コース名称 (新修の目的 (11)11到達目標 (12)12協力期間 (12)12時期・期間 (12)13割当国 (13)13定員 (応募資格 (14)14
4 - 4 - 4 - 4 - 4 -	- 1 - 2 - 3 - 3 -	8実施機関の概要 15 組織及び活動 16 関連組織及び支援機関 16 研修実施能力 16 -1 技術的側面 16 -2 運営的側面 17 施設・機材等 17 子算 18
κ .	- 1 - 2	R保健機構(WHO)との協力 本部での打ち合わせ
付店	萬資料	부 -
;	2 I 3 V 4 (関査団討議議事録(ミニッツ) R / D W H O との往復書簡 G. I 貞熱病対策フレームワーク(W H O 作成ペーパー)

1 事前調査団の派遣

1-1 調査団派遣の経緯と目的

- (1) わが国は、1968年にガーナ大学医学部に対する保健・医療分野の技術協力を開始し、その後、1979年までに、「ウィルス学と電子顕微鏡」、「低栄養と感染症」、「病態生理学と免疫学」等をタイトルとした技術協力を継続的に実施してきた。これらの技術協力は、1977年及び78年に無償資金協力によって設立された医学部付属野口記念医学研究所(野口研)にその活動の拠点が移され、それ以後、野口研を舞台として、文字通り、技術協力と無償資金協力が有機的に結びついた西アフリカ地域における代表的なモデルプロジェクトとして長い間内外の注目を集めてきた。
- (2) このように、野口研の設立を受けて、わが国の技術協力は更なる展開を見せることとなり、1980年に開始された「下痢症と低栄養」、86年度に開始された「野口記念医学研究所プロジェクト」では、ウィルス学、栄養学、及び疫学の3分野でプロジェクト方式の技術協力が行われてきた。
- (3) 一方、世界保健機構(WHO)は、UNICEF等との協力により、西暦2000年までにポリオ (急性灰白髄炎)を地球上から撲滅させる目標のもとにポリオ撲滅運動 (Polio Eradication Initiatives)を展開してきた。これまでに、南北アメリカ大陸での成功、大洋州や中国での進展を受け、アフリカ地域を南西アジア地域と並ぶ最後の重要拠点として位置付けて積極的な取組を行ってきた。このような中で、1989年、WHOは、わが国の資金・技術協力により設立された野口研をアフリカ地域における最初の地域研究所 (Regional Reference Laboratory) に指定するに至った。
- (4) このような事情を背景として、1990年4月に、わが国とWHOとの初めての定期協議が開催されたが(1992年まで3回実施されそれ以後中断)、右定期協議の場において、野口研を実施機関とするポリオ診断分野の第三国研修実施に関して両者の協力が合意された。
- (5)第三国集団研修「ワクチン力価試験及びポリオ関連診断技術」コースは、最初のマルチ・バイによる第三国研修として1991年度から5年間にわたり、野口研を舞台に実施された。この第三国研修は、1995年7月に行われた終了時評価調査において、アフリカ地域におけるポリオ診断技術者の養成及び研究所間ネットワークの確立に貢献したことが確認された。

- (6) 右評価調査においては、WHO、JICA及び野口研の三者によるマルチ・バイ協力の有効性が立証されたことを背景に、近年、アフリカ諸国において流行の兆が顕著となっている黄熱病分野の診断技術普及の緊急性が提示されるとともに、本件分野での第三国研修における協力の可能性の検討が提案された。
- (7) 95年10月、ガーナ国政府より、わが国政府に対して、「黄熱病等EPI関連感 染症診断技術」に関する第三国研修の実施に係る要請書が提出された。
- (8)本件要請を受けて、JICAは、本件第三国研修の実施可能性を確認し、研修範囲・内容、関係者間(WHO及び野口研)の業務分担等について協議するとともに、実施に向けたガーナ側との協議議事録案を取り纏めることを目的として調査団を派遣することとした。

1-2 調査団の構成

タカハシ	ヨシユキ		
高橋	嘉行	団長・総括	国際協力事業団研修事業部研修第三課長
719	£ 1. A		
有田	蜂生	感染症対策	厚生省国立予防衛生研究所ウィルス製剤部長
サカモト	ジュン		
坂本	純	医療協力政策	厚生省大臣官房国際課国際協力専門官
ホソカワ	ヒロシ		·:
細川	博	研修計画	国際協力事業団研修事業部研修管理課

1-3 調査日程

日順	日 時	曜	行 程	訪問機関	調査内容
1	08 - 22	木	1150 東京発(JL-401) 1625 ロンドン着 1905 ロンドン発(BA-732) 2135 ジュネーブ 着	-	
2	08 • 23	金	1000	世界保健機構(WHO)	WHOとの業務分担について協議、基本的な合意を得る。
3	08 - 24	土	0700 ジュネーブ 発(LH-457 0825 フランクフルト 着 1220 フランクフルト 発(LH-5 1645 アクラ 着		
4	08 - 25	B			(調査準備)
5	08 - 26	月	0900 1000 1100 1145 1400 1600	JICA事務所 日本大使館 大蔵省対外経済関係局 保健省 野口英世記念医学研究所 教育省	調査方針及び日程の打合せ 田中大使表敬訪問 局長表敬及び調査への協力依頼 保健大臣表敬訪問 所長表敬及び調査日程の打合せ 次官及び高等教育局長表敬訪問
6	08 • 27	火	0900 1400	野口英世記念医学研究所 ガーナ大学	第三国研修に係る協議開始 学長補佐表敬訪問
7	08 · 28	水	0900(高橋、細川) 0900(有田、坂本) 1700	野口英世記念医学研究所 コルフ病院及びニャわリニック WHOガーナ事務所	第三国研修に係る協議継続 病院視察及び意見交換 表敬訪問及び意見交換
8	08 • 29	木	0900 1400 1500 1600	野口英世記念医学研究所 保健省 教育省 国立公衆衛生研究所	第三国研修に係る協議継続 次官補に対する調査結果の報告 次官に対する調査結果の報告 施設見学
9	08 · 30	金	1030 1130 1500 2300 799 発(BA-078)	野口英世記念医学研究所 大蔵省対外経済関係局 日本大使館	協議議事録(ミニッツ)の署名 局長に対する調査結果の報告 若杉公使に対する調査結果報告
1 0	08 - 31	土	0630 ロンドン着		
1 1	09 • 01	П	1945 のドン発 (JL-402)		
1 2	09 • 02	月	1525 東京着		

1-4 主要面談者

大蔵省

William Adote

Director, International Economic Cooperation Division

Agnes Batsa

Head, Bilateral Relations

Kwasi Opoku

Japan's Desk Officer

Edmund Nkansah

Japan's Desk Officer

保健省

Brookman Amissah

Minister

J. D. Otto

Acting Director of Medical Services

Kofi Ahmed

Director, Public Health Division

教育省

Dalrymple Hayfron

Chief Director

De Heer Amissah

Executive Secretary of Tertiary Education

ガーナ大学

James Anguandah

Acting Vice Chancellor

コル・レブ教育病院

K. K. Pumpuni

Hospital Administrator

公衆衛生研究所(Public Health and Reference Laboratory)

Asamoah Adu

Head

ニャホ・クリニック

Nyaho Tamakloe

Director

世界保健機構(WHO)

J. W. Lee

Director, Gloval Programme for Vaccines

and Immunization (GPV)

Hiroyuki Doi

Medical Officer, GPV (厚生省から出向中)

J. Cheyne

Programme Officer, GPV

Michel Zaffran

Technical Officer, Expanded Programme on Immunization

Barbara P. Hull

Technical Officer, GPV

O. Tomori

Virologist, WHO-AFRO

Martin T. Mandara

Country Resident Representative, Ghana

Fleisher Djoleto

Health Officer, Ghana

Avoke

Health Officer, Ghana

野口記念医学研究所

Francis Nkrumah

A. K. Nyorka

Mubarak Osei

P. G. Addo

I. A. Brandful

Opoku Agyarkwa

Toshiya Kamiya

Director

Deputy Director

Head, Virology Unit

Head, Animal Unit

Research Fellow, Virology Unit

Administrative Secretary

JICA Project Leader

日本大使館

- 田中 明久

慎

若杉 本田俊一郎 特命全權大使

公使

専門調査員

JICAガーナ事務所

八林 明生

小瀬川 修

阿部記実夫

事務所長

次長

所員

Rabi Ali Administrative Secretary

2 要請の背景


2-1 周辺国の研修ニーズ

世界保健機構 (WHO) の報告によれば、現在、アフリカ諸国のうち赤道をはさむ 33か国が黄熱病の危険地域として指定されている (次項 図1参照)。

黄熱病は、17世紀の中頃にバルバドス諸島、キューバ、メキシコにおいて最初の発生が記録され、その後18世紀から今世紀初めにかけて、カリブ諸島、南アメリカ、あるいはアメリカ合衆国の港町での発生が報告されている。アフリカ大陸での最初の発生は1778年のセネガルで記録された。1980年初頭から黄熱病の発生はアフリカがそのほとんどを占める状況となり、特に85年以降は報告される発生報告の90%以上がアフリカにおけるものとなっている。(次項 表1参照)

黄熱病は、熱帯雨林に棲息する蚊を媒介としたウィルス性の感染症であり、多くの場合、森林地帯で木材の伐採作業に携わる労務者を通じて、都市等の人口密集地域にもたらされると考えられる。典型的な症状としては、突然の高熱、悪寒、頭痛、背痛、筋肉痛、吐き気、嘔吐に加えて黄疸や出血等が見られる。

黄熱病は、ワクチンにより予防可能な感染症である。潜在的な危険地域である西アフリカ諸国においては、1940年代に天然痘撲滅のための大規模なワクチン接種運動の中で、黄熱病ワクチンが天然痘ワクチンと同時に接種されたことから、1980年代中頃までには、大規模な発生が報告されることはなかった。



YELLOW FEVER EPIDEMICS IN AFRICA

<u>YEAR</u>	COUNTRY	_CASES/DEATHS_(reported)
1958	ZAIRE	60/23
1959	SUDAN	120/88
1960~62	ETHIOPIA	100,000/30,000
1964	GUINEA	6/6
1965	SENEGAL 2,000	\sim 20,000/(up to 44%)
1966	ETHIOPIA	7/350
1969	GHANA	250/73
1969	MALI	21/12
1969	BURKINA FASO	3,000/100
1969	NIGERIA	100,000/40,000
1970	NIGERIA	786/40
1971	ANGOLA	65/42
1975	SIERRA LEONE	130/36
1977~79	GHANA	434/120
1978~79	GAMBIA	8,400/1,600
1981	SENEGAL.	2/0
1982	COTE D'IVORE	25/25
1983	BURKINA FASO	12,500/?
1986~91	NIGERIA	30,000/7,500
1992~93	KENYA	54/28
1993	GHANA	?
1994	NIGERIA	128/80
1994	GABON	?/54
1994	KENYA	78/8
1995	LIBERIA	?

^{*} all the data were extracted from WHO paper

しかしながら、1990年代に入り、多分に天然痘の絶滅による予防接種の中止により、再びアフリカ諸国において発生が顕著となってきている。最近では、91年にナイジェリア、92年にケニア、93年にケニア、ガーナ、94年にナイジェリア、ガボン、ケニア、95年にはリベリアでの発生が報告されている(別紙 表参照)。ちなみに、1990年代になって発生した黄熱病の約25%は5才以下の子供が患者となっている。このため、1988年には、WHOとUNICEFの合同予防接種技術会議において、EPIプログラムの中に黄熱病を含めることが提案された。

一方、アフリカ諸国における黄熱病ワクチンの予防接種カバレージは極めて低いレベルにとどまっている。危険国に指定されている33か国の中で成人の予防接種率で45%以上を達成しているのはたった4か国に過ぎない。黄熱病ワクチンがワンショット0.18USドル(WHO報告による)であることが接種率向上の阻害要因のひとつとなっているものと考えられる。黄熱病ワクチンの場合接種証明書ではその有効期限が10年となっているが、一度予防接種を受ければ、生涯にわたり一定の予防効果が持続するものと考えられている。

黄熱病の蔓延を防止するためには、ワクチンの接種と並んでサーベイランスシステムの構築が極めて重要である。これについては、アフリカ各国で既に確立されている EPI (ポリオ、麻疹等) サーベイランスシステムを準用することが可能である。黄熱病はウィルス性肝炎、マラリア等と極めて似た初期症状を呈することから、迅速かつ正確な初期診断が黄熱病の蔓延を未然に防ぐ上での重要な要件となっている。

2-2 実施国における当該分野の現状

ガーナでは黄熱病の発生が比較的頻繁に報告されている。1950年以降だけでも、69年、77年から79年にかけて、更に、83年、93年にそれぞれ記録されている(WHO報告による)。

多くの日本人が、かつて小学校の教科書で学んだとおり、野口英世博士が黄熱病研究のためにロックフェラー研究所から派遣され、志半ばの1928年5月に、まさに黄熱病によって倒れるまでの短い間を過ごしたアフリカの瘴癘の地がガーナである。このことからも、昔からガーナが黄熱病ウィルスの生息地として適した自然環境にあったことは疑いない。

わが国政府は、野口英世博士の偉業をたたえて、ガーナ大学医学部を通じて196 0年代から保健医療分野での技術協力を継続的に行ってきており、特に79年の野口 記念医学研究所の設立以降は、同研究所をわが国の西アフリカ地域における医療協力 の拠点施設としてプロジェクト技術協力を中心とした複合的な取組を行ってきた。

これらの状況を踏まえ、1991年に開始された同研究所を実施機関とするポリオ 診断分野の第三国研修が、WHOの支援を得つつも成功裡に終了したことは野口研の 研修実施機関としての運営能力を広く確認させることとなった。

3 調査結果の概要 (第三国研修基本計画)

3-1 コース名称

英文名: Laboratory Diagnosis of Yellow Fever and Other EPI Viral Diseases
(Polio and Measles)

和文名:黄熱・ポリオ実験室内診断技術

本件コースにおける主な対象疾病は黄熱病であり、研修の目的も、参加国の試験研究 機関で黄熱病を担当する検査技師に対し、早期診断技術を習得させることにある。

しかしながら、アフリカ諸国における感染症の試験研究機関では、検査技師が黄熱病、ポリオ等疾病毎に専門化している訳ではなく、多くの場合、複数の感染症を兼ねて担当しているのが実態である。加えて、ポリオ及び麻疹については昨年までのコースで一定の診断技術が習得されたものと考えられるが、継続的なフォローアップの重要性が指摘されている。これらから、今次コースにおいてもポリオ及び麻疹についての診断技術をカリキュラムの一部に加えることが必要であると認められた。

この結果、コースの正式(英文)名称を黄熱病に加えて他のEPIに定められるウィルス性感染症の実験室内診断技術とし、括弧の中にポリオ及び麻疹を示すこととした。

一方、和文名称については、アフリカ大陸におけるポリオ根絶に対するわが国協力の 継続性を強調する目的からポリオの名前を明示することとした。

3-2 研修の目的

本件第三国研修の目的は、アフリカ諸国のうち、WIIOにより黄熱病の危険地域として指定されている国の試験研究機関の検査技師に対して、それぞれの参加国において定められた感染症対策撲滅計画 (National Disease Control and Eradication Programme) 推進を支援する一環として、黄熱病、ポリオ及び麻疹の実験室内診断技術を習得させることである。

3-3 到達目標

各回のコース終了時において、参加研修員は以下の知識及び技術を習得していること が期待される。

- (1) 黄熱病、ポリオ、麻疹診断に関する基礎的知識及び実用面を重視した標準的な実 験室内検査技術
- (2) 黄熱病、ポリオ、麻疹等の生ワクチンの有効性試験に係る知識及び技術の鍛錬
- (3) 黄熱病、ポリオ、麻疹に関するアフリカ地域における対策・撲滅目標の認識とこれを達成するための試験研究機関の役割の理解

3-4 協力期間

本件コースで、アフリカ地域における黄熱病サーベイランスシステムを確立し、感染の早期診断を行うための必要最小限の施設・機材を有する試験研究機関の数及びそれぞれの機関における関連検査技師の人数等を考慮し、本件研修実施の協力期間を1996年度から1998年度までの3年間とすることで合意した。

3-5 時期・期間

研修の時期については、前回コースとほぼ同様とすることで基本的に合意されたが、 3月31日までに研修経費の精算を終えるため、前回コースより約10日間繰り上げ、 第一回目のコースを1997年2月24日から開始することで合意された。

また、研修期間については前回コース同様に17日間とすることで合意された。

3-6 カリキュラム

カリキュラムは別紙*に示すとおりであるが、基本的には午前中に講義、午後に関連する実技・実習を行うように計画されている。また、土曜日、日曜日を除く15日のうち、EPI全体に関しては1日、黄熱病に関しては7日、ポリオに関しては3日、麻疹に関しては2日、最終試験及びコース評価に2日の配分となっており、黄熱病を中心のテーマとしたコースであることが明確となっている。

3-7 割当国

本件コースへの参加が想定される国は、WHOにより黄熱病の危険地域に指定されているアフリカ33か国であるが、本件コースが英語で実施されること、本件コースで提供される検査・診断技術を適用するために十分な施設・機材を有している国(具体的には研究所)であること、及び、研修機関(野口研)の受容能力等を総合的に勘案し、本件調査の段階で、以下の8か国が割当国として指定された。

カメルーン、エリトリア、エチオピア、ケニア、シエラ・レオーネ、タンザニア、 トーゴ、ウガンダ、(リベリア)

ところでリベリアの取扱いについて、調査団の帰国後に外務省と改めて協議した結果、研修員応募に係る実施国(ガーナ)政府とリベリア政府との正式な外交ルート(具体的にはリベリアにおけるガーナ大使館の存在)が確認できたことから、R/Dの中に割当国として追加することとなった。この結果、本件コースへの割当国は最終的に9か国となる。

一方、ナイジェリアは人口規模や国内の劣悪な衛生状況を考慮すると黄熱病による被害の危険性が最も高い地域であると考えられるが、国内の民主化の遅れ等により、現在、わが国政府開発援助 (ODA) の供与が停止されていることから、同国からの研修員についてはWHOが経費を負担して参加させることとなった。

3-8 定員

本件コース実施機関である野口研のウィルス部の施設・機材の状況から、受け入れ可能な研修員は12名であることが確認された。これにより、割当国から最大で10名、ガーナ国内から最大で2名の研修員、合計12名を定員とすることとなった。

これら12名の研修員は、それぞれ3つのグループに別れて実習を行うこととなる。

WHOの経費負担によるナイジェリア、ガンビア等わが国のODA供与が停止されている国からの研修員の数は全体の4分の1を越えないこと(3名以内)が日頭ながら確認された。

3--9 応募資格

本件コースへの応募資格は以下のとおりに定められた。

- (1) 応募国の推薦を受けたものであること。
- (2) コース参加を通じて習得した知識・技術を帰国後に活用することを応募国政府が約 東するものであること。
- (3) 感染症診断に係る技術に関する学位、あるいは上級技術資格(Advanced Technical Diploma)を有するものであること。
- (4) EPI (WHOの推進する予防接種拡大計画) に関連したウィルス診断やワクチン の効力試験を実施している研究機関に勤務する科学者あるいは上級検査技師である こと。
- (5) 微生物学に関する5、6年の業務経験及び最低一年のウィルス病に関する業務経験 を有すること。
- (6) 原則として、45歳以下であること。
- (7) 英語での読み書きに堪能なこと。
- (8) 心身共に健康であること。

4 研修機関の概要

4-1 組織及び活動

野口記念医学研究所は、1977年及び1978年に総額20億円に及ぶわが国無債資金協力によって設立されたガーナ大学医学部付属の研究所であり、ガーナの首都アクラ市の北方約10キロのレゴン地区に位置している。

1991年より二代目の研究所長としてガーナ独立の父として広く尊敬を集めている 故エンクルマ大統領の息子であるフランシス・エンクルマ氏が就任し、今日に至ってい る。父親の威光を背景としてエンクルマ所長のカリスマ性が同研究所の長所でもあり、 また、短所ともなっている。つまり、エンクルマ所長の影響力は大きく、例えば、研究 所の予算の確保等にあたっては、かなりの威力を発揮しているものと想像される一方、 研究所の研究活動及び研究所の運営全体に関して権限の一極集中が顕著であり、同研究 所の人材及び組織育成を阻害している面も見逃せない。

エンクルマ所長は、また、アフリカ地区における感染症学会の主要メンバーであり、WHO等の国際機関において同研究所のみならずアフリカ地域における発言力維持の源ともなっている。

WHOは、エンクルマ所長の存在、及びわが国無償資金協力による施設・機材の整備と並んで継続的に実施されてきたプロジェクト技術協力の成果を評価し、1989年には同研究所をアフリカ地域における感染症対策の拠点研究所(Regional Reference Laboratory)に指定された。

4-2 関連組織及び支援機関

本件第三国研修はWHOの技術的な支援を得て実施されるいわゆるマルチ・バイ協力であり、コース実施のためWHOから毎回2名の講師が派遣される他、WHOの開発したテキスト及び関連試薬等の提供も予定されている。

研修員の宿泊施設として、ガーナ大学のゲストハウスが提供される予定であるが、 WHO派遣の講師を含めたすべての関係者が文字通り寝食を共にすることで、単に関連 技術の習得のみならず参加各国の保健・衛生の諸問題を含めた幅広い交流が期待される。

また、WHOに対しては参加各国のカントリーオフィースを通じた研修員の適切及び タイムリーなリクルート等、本コース実施に向けたサブ・ロジ両面での支援が期待される。

一方、ガーナに限らず、アフリカ諸国に共通的に見られることであるが、感染症予防・対策を効果的に実施するためには、試験研究機関と医療行政機関との、具体的には、ガーナにおける大学の研究機関あるいは科学研究省と保健省との有機的な連係の強化が不可欠であるが、本件コースの実施国であるガーナにおいても、両者の関係が円滑に行われている、あるいはそのためのシステムが機能しているとはいいがたい状況にある。この点においてもWHOの積極的な働きかけや指導が期待されるところでもある。

4-3 研修実施能力

4-3-1 技術的側面

本件第三国研修の実施機関である野口研は1991年度から1995年度までの5年度に渡り、第三国研修「ワクチンカ価試験及びボリオ関連技術」コースの実施を担当した。1995年7月に実施された右第三国研修評価調査において、WHO及びJICAからの技術援助を受けたものの、野口研からも講師2名の配置及び実習における助手の配置等を積極的に行ったことが評価されており、今次第三国研修の実施にあたっても同様の役割達成は十分に可能と考えられる。

また、今回の第三国研修においては、マウスやモルモット等の小動物を使った感染実験が行われるため、大量の小動物飼育技術が必要とされることが判明している。野口研には動物ユニット担当部局が既に存在しているが、平成8年度第三国研修カウンターバートの本邦研修の一環として同部の技術者の研修を実施し、第三国研修に向けた技術的な準備を行うこととした。

4-3-2 運営的側面

一野口研の第三国研修に係る運営に関し、前回のコースにおいては、コースの実施時期が年度末に設定されていたため、支払い、精算業務を含む研修に係る経費の全ての取扱いをJICA事務所が代行して実施されていた。しかしながら、今回の調査において、野口研のこれら研修事業の運営能力を開発、向上させるため、今次コースについては、実施機関である野口研に支払い、精算業務のすべてを担わせることとした。

また、コースG I 等の作成については、従来通り、WHOアフリカ事務所の技術支援を受けて実施されることとなるが、前回コースにおいてエンクルマ所長不在にあってはG I の送付等の純手続き的な事項についても決裁なしには済まないため、所要の手続きに遅れを来すことが多かったが、この度、野口研に新たに副所長が任命されたこともあり、権限の副所長への委譲等について期待できる状況ができ上がっている。

4-4 施設・機材等

これまで繰り返し述べてきたように、野口研はわが国無償資金協力を得て設立され、 アフリカの水準でいえば極めて整備された状況にあり、また、それに続くプロジェクト 技術協力においても機材・備品が更に充実される等、本件研修に必要な基本的なものは 既に十分に備えつけられていることが確認された。 しかし、今次第三国研修においては、実験小動物(マウス、モルモット等)が多頭必要となるため、同研究所の動物ユニットでの繁殖・飼育が不可欠となる。このためにはこれら小動物を飼育する籠(ケージ)を調達する必要があるところ、第三国研修のための消耗品としてJICAの資金援助により購入することとした。ただし、消耗品といっても一回毎に買い替えることは必要がなく、3回のコースに共通して使用されることとなる。

一方、前回のコースでは、研修実施に必要な各種消耗品は、並行して実施されている プロジェクト技術協力専門家の携行機材によりその大部分が手当てされていたが、今次 コースについては可能な限り研修経費として計上することとしプロジェクト技術協力へ の依存を極力排することとした。

4-5 予算

本件研修の実施に必要な経費について、今回の調査ではその全容を明らかとすることはできなかったが、JICAが負担するものについては概略別紙2に示すとおり。WHOはWHO派遣専門家の経費及び関連テキスト及び試薬購入に係る経費を負担することとなる。また、当然のことながら、本件研修を実施する上でガーナ側が負担することとなる間接経費は想定されることとなり、全体としては、関係者それぞれが応分の負担をすることになることはいうまでもない。

5 世界保健機構 (WHO) との協力

5-1 WHO本部での協議

調査団は、ガーナへの途上でジュネーブに立ち寄り、世界保健機構(WHO)本部において、WHOにおける担当部局となるワクチン予防接種計画部局を訪問し、本件第三国研修に関するWHO側の意向を確認した。

WHOは、前回の「ポリオ診断コース」においてWHO、JICA、ガーナ政府(野口研)の三者協力による試みが成功したことを踏まえ、第二フェーズとなる本件コースの実施について積極的に日本側及びガーナ側に働きかけてきた経緯を踏まえ、以下に示す通り前回とほぼ同様の協力を行う意志を明確に示した。

- (1) コース指導者2名の派遣 (WHOの経費負担による)
- (2) 黄熱病ウィルス診断に係るテキストの提供
- (3) 関連検査用試薬の提供

更に、研修コースの準備を円滑に進めるために、研修コースGIの作成及びWHOの各国カントリー事務所を通じた研修員リクルートに対する支援が確認された。

この、WHO側からの協力については、本件第三国研修の実施が形の上では日本とガーナ政府の二国間の約束に基づいて実施されるものであり、従って、二国間の正式文書となるR/D等に明示的に含めることはできないことから、R/Dの署名が終了した段階で、JICAとWHOの間で改めて書簡交換の形で取り交わすこととした。具体的な手類としては、R/Dへの両国政府の署名が終了した後に、JICAはWHOに報告し、これを受けてWHOは内部手続きを経た上で協力内容についてJICAに書簡の形で連絡をすることとした。

5-2現地での協議

今回の第三国研修事前調査にWHOは、本部担当者のハル博士及びWHOアフリカ地域事務所のウィルス学者であるトモリ博士を参加させた。両名は調査団の野口研側との協議に終始参加し、野口研側にWHOの従来通りの協力について保証を与えるとともに、研修実施に必要な機材、消耗品の確認及びコースGIドラフト案の作成について積極的に支援を行った。WHOの協議への参加により野口研側との協議は極めて円滑に進み本件調査の成功に寄与したものと評価される。

6 团長所感

本件第三国研修は、1991年から1995年にかけて成功裡に実施された「ワクチンカ価試験及びポリオ関連診断技術」コースに引き続いて実施される、いわばマルチ・バイ協力の第二フェーズと目されるものであり、いわゆるレギュラーメンバーとなった野口研、WHOとJICA (及び厚生省国立予防衛生研究所)との合同によるアフリカ地域での感染症対策の切り札的なコースとなっている。

アフリカにおけるポリオを始めとする熱帯性感染症の予防、対策は、マラリアと並ぶ保健上の最大の課題であり、わが国政府も従来から単独機材供与、あるいは無償資金協力等の多彩なプログラムにより継続的な協力を行ってきた。更に、1996年4月に、池田外務大臣が南アフリカで開催された国連貿易と開発会議(BNCTAD)総会においてアフリカ地域の保健衛生分野の向上に引き続き積極的に取り組む姿勢を表明した。

このような中で、研修を始めとする技術協力による人造り事業は、ワクチンやコールドチェーン等の機材供与の有効性を一層高める上で、更には人と人が直接に接するいわゆる「顔の見える援助」を具現化する上で極めて重要な事業である。

しかしながら、アフリカ地域における保健、医療分野の状況に関する、わが国関係者の知見は必ずしも十分なものとはいい難いのが現状である。一方で、いわゆる国家という人為的な境界を何等の障害もなく越えて跋扈する黄熱病のような災禍に立ち向かうためには、国家の枠を越えた地域的な対応が不可欠である。

このような観点から、従来の二国間の協力の仕組みでは対応できないケースにおいては、WHO等の国際機関の地域戦略の中でそれら機関の有する情報やノウハウを十分に活用しながら対応することが極めて重要であり、その意味ではJICAとして、本件第三国研修のみならず、他の分野においてもこれらの国際機関との協調に一層積極的に取り組むことが求められてきていると考えられる。

本件第三国研修コースがアフリカにおけるマルチ・バイ協力の有効性を証明する成功 プロジェクトとなるよう切に希望するものである。

MINUTES OF MEETINGS BETWEEN THE JAPANESE PRELIMINARY SURVEY TEAM AND

THE AUTHORITIES CONCERNED OF THE GOVERNMENT OF THE REPUBLIC OF CHANA ON

THE THIRD COUNTRY TRAINING PROGRAMME

The Japanese preliminary survey team, organized by the Japan International Cooperation Agency (hereinafter referred to as "JICA") and headed by Mr. Y. Takahashi, visited Ghana from the 24th to the 30th of August, 1996, in order to discuss with the authorities concerned of the Republic of Ghana a training course for participants from African countries in the field of Laboratory Diagnosis of Yellow Fever and Other EPI Viral Diseases (Polio and Measles), to be conducted in Ghana under the Third Country Training Programme of JICA.

After a series of meetings, both sides have come to a conclusion that the training course will contribute to strengthening research capabilities in the field of Laboratory Diagnosis of Yellow Fever, Polio and Measles in African countries.

Both sides drafted the Record of Discussions attached as APPENDIX I, and agreed to recommend to their respective Governments that necessary actions should be taken in order to ensure the successful implementation of the training course.

A list of attendants at the meetings is attached as APPENDIXII.

in Accra, on the 30th of August, 1996

France Chunal

Mr. Yoshiyuki TAKAHASHI

Head of the Japanese Survey Team, Japan International Cooperation Agency Prof. Francis Kwesi NKRUMAH Director, Noguchi Memorial Institute for Medical Research, University of Ghana

RECORD OF DISCUSSIONS BETWEEN THE RESIDENT REPRESENTATIVE OF JICA GHANA OFFICE AND

THE AUTHORITIES CONCERNED OF THE GOVERNMENT OF THE REPUBLIC OF GHANA ON

THE THIRD COUNTRY TRAINING COURSE

IN THE FIELD OF
LABORATORY DIAGNOSIS OF YELLOW FEVER AND OTHER EPI VIRAL DISEASES

(POLIO AND MEASLES)

The Japanese Preliminary Survey Team, organized by the Japan International Cooperation Agency (hereinafter referred to as "JICA") and headed by Mr. Y. Takahashi, visited the Republic of Ghana between the 24th and 30th of August, 1996, had a series of discussions with the authorities concerned of the Republic of Ghana at Noguchi Memorial Institute for Medical Research, University of Ghana (hereinafter referred to as "NMIMR") with respect to the framework of a training course in the field of Laboratory Diagnosis of Yellow Fever and Other EPI Viral Diseases (Polio and Measles) under the Third Country Training Programme of JICA, and desirable measures to be taken by both Governments to ensure the successful implementation of the training course.

Based on the Minutes of Meetings concluded between the head of the Japanese Team and the director of NMIMR and subsequent dialogues, the two parties have agreed to recommend to their respective Governments the matters referred to in the documents attached hereto.

at Accra on th of Sept., 1996

Mr. Akio YATSUBAYASHI Resident Representative, JICA Ghana Office Prof. George BENNEH Vice Chancellor, University of Ghana



NB

ATTACHED DOCUMENT

The Government of Japan and the Government of the Republic of Ghana will cooperate with each other in organizing a training course in the field of Laboratory Diagnosis of Yellow Fever and Other EPI Viral Diseases (Polio and Measles) for participants from African countries (hereinafter referred to as "the Course") at NMIMR under the Third Country Training Programme of JICA.

The Course will be held once a year from Japanese fiscal year 1996 to 1998, subject to an annual consultation between both Governments.

The Course will be conducted in accordance with the following;

1 TITLE
The Course is entitled "Laboratory Diagnosis of Yellow Fever and Other
EPI Viral Diseases (Polio and Measles)".

2 PURPOSE

The purpose of the Course is to provide participants from African countries at risk of Yellow Fever with laboratory skills to diagnose yellow fever, polio, and measles in support of National Disease Control and Eradication Programmes.

3 OBJECTIVES

At the end of the Course, participants are expected;

- 3-1 to have gained basic knowledge and practical aspects of standard laboratory techniques for the diagnosis of yellow fever, polio, and measles,
- 3-2 to have improved their knowledge and skills in the potency testing of live viral vaccines of yellow fever, polio, and measles,
- 3-3 to have understood the regional control and eradication goals for those diseases, and the role of laboratories in achieving them.



S

- 4 <u>DURATION</u>
 The first Course will be held from February 24th to March 14th, 1997.
- 6 INVITED COUNTRIES
 The Governments of the following countries will be invited to apply to the Course by nominating applicant(s);

Cameroon, Eritrea, Ethiopia, Kenya, Sierra Leone, Tanzania, Togo, Uganda

Note: WHO may sponsor participants from countries other than those listed above.

7 NUMBER OF PARTICIPANTS The number of participants shall not exceed twelve(12) in total. The number of participants from invited countries and that from Ghana

The number of participants from invited countries and that from Ghana shall not exceed ten(10) and two(2) respectively.

8 <u>FACILITIES AND INSTITUTIONS</u> Noguchi Memorial Institute for Medical Research, University of Ghana is the venue for the Course.

9 QUALIFICATIONS FOR APPLICANTS Applicants for the Course are;

- 9-1 to be nominated by their respective Governments in accordance with the procedure to be mentioned in the following chapter,
- 9-2 to be engaged by the nominating Governments so that the skills obtained through the Course will be appropriately utilized on their return.
- 9-3 to have an appropriate university qualification or advanced technical diploma,
- 9-4 to be scientists or senior technologists in laboratories engaged in diagnostic virology and vaccine potency testing in EPI,
- 9-5 to have practical experience of several years in microbiology and at least one year's bench experience in virology,
- 9-6 to be under forty-five(45) years of age, as a rule,
- 9-7 to have a good command of spoken and written English, and
- 9-8 to be in good health both physically and mentally, to complete the Course.



NB

10 APPLICATION PROCEDURE

- 10-1 A Government applying for the Course shall forward two(2) copies of prescribed application form for each nominee to the Government of the Republic of Ghana through diplomatic channels not later than sixty(60) days before the commencement of the Course.
- 10-2 The Government of the Republic of Ghana will inform the applying Governments through diplomatic channels whether or not the applicant(s) is/are accepted for the Course not later than thirty(30) days before the commencement of the Course.
- In organizing and implementing the Course, both Governments will take the following measures in accordance with relevant laws and regulations in force in each country. The tentative schedule of implementation for the first Course is attached as ANNEX II.
 - 11-1 The Government of the Republic of Ghana
 - 11-1-1 The Ministry of Finance:
 - (1) To forward general information brochures (G. I.) to the Governments of invited countries through diplomatic channels.
 - (2) To receive application forms and forward them to NMIMR.
 - (3) To notify the results of judgment upon applications to respective applying Governments through diplomatic channels.
 - NOTE: To facilitate the above mentioned procedures, the Government of Ghana will be supported by WHO and/or JICA when necessary.
 - 11-1-2 Noguchi Memorial Institute for Medical Research:
 - (1) To formulate the curriculum based on ANNEXI.
 - (2) To draft and print the G. I.
 - (3) To assign an adequate number of staff as instructors/research assistants to the Course.
 - (4) To provide training facilities and equipment for the Course.
 - (5) To select participants for the Course, and notify the results of the selection to the Ministry of Finance and JICA Ghana Office.
 - (6) To arrange accomodation in Ghana for the participants.
 - (7) To arrange international air tickets for the participants from the invited countries and to meet and to see them off at an airport in Ghana.



b

- (8) To arrange domestic study tour (s) to be included in the Course.
- (9) To make budgetary allocations to cover the cost in conducting the Course, excluding the expenses to be borne by JICA.
- (10) To issue certificates to the participants who successfully complete the Course.
- (11) To prepare and submit a course report to the JICA Ghana Office within thirty (30) days after the termination of the Course.
- (12) To submit a statement of expenditure for the verification thereof to the JICA Ghana Office within thirty(30) days after the termination of the Course.
- (13) To coordinate any matters related to the Course implementation.

11-2 The Government of Japan:

- (1) To dispatch Japanese short-term expert(s), in accordance with the normal procedures of its technical cooperation scheme, who will support the staff of NMIMR to facilitate the implementation of the Course,
- (2) To bear the following expenses through JICA (the tentative estimate of expenses for the first Course is attached as ANNEXIII).
 - ① expenses relevant to participants from invited countries such as international economy-class flight fare, accommodation, per diem, medical insurance premium, etc.,
 - ② expenses relevant to NMIMR such as study tours, texts, teaching aids, expendable supplies, copies and reprints, secretarial services, opening and closing ceremonies, etc.

NOTE: Technical and material support of WHO would be expected based upon discussions to be made respectively between WHO and NMIMR; and between WHO and JICA.

12 PROCEDURE FOR REMITTANCE AND EXPENDITURE

Remittance of funds for expenses to be borne by the Government of Japan and the expenditures thereof will be arranged in a following manner:

- 12-1 NMIMR will open a bank account in Ghana to receive the funds to be remitted by JICA, and inform the JICA Ghana Office of the names of the bank and the account holder and the account code number.
- 12-2 NMIMR will submit to the JICA Ghana Office a bill of estimate for the expenses to be borne by the Government of Japan not later than ninety (90) days before the commencement of the Course.
- 12-3 JICA will assess the bill of the estimate and remit the assessed amount of expenses to the account mentioned in 12-1 above not later than forty-five (45) days after the receipt of the bill of estimate.



No

- 12-4 NMIMR will submit to the JICA Ghana Office a statement of expenditure within thirty (30) days after the termination of the Course.
- 12-5 In case there is any unspent amount remitted by JICA, NMIMR will reimburse it to JICA in accordance with advice given by the JICA Ghana Office. The funds allocated for the flight fare, accomodation, per diem, and medical insurance premium shall not be appropriated for any other purposes.
- 12-6 When requested by JICA, NMIMR will make available for JICA's reference all the receipts and other documentary evidence to verify the expenditure stated in 12-4 above.

13 OTHERS

This attached document and the following ANNEXes attached hereto shall be deemed to be part of the Record of Discussions.

Annex I: Tentative Curriculum of the Course (for JFY 1996)
Annex II: Tentative Schedule of Implementation (for JFY 1996)

Annex III: Tentative Estimate of Expenses to be borne by the Government of Japan (for JFY 1996)



NB

Annex I

Tentative Curriculum of the Course (for JFY 1996)

Day 1 Lecture: The Expanded Programme on Immunization: Disease Control and

Eradication Initiatives

The Role of the Laboratory in the Control and Eradication

of Diseases

Practical: Maintenance and Cryopreservation of Cell Cultures

Day 2 Lecture: Global History of Yellow Fever/Overview of Yellow Fever

in Africa

Practical: Isolation of YF Virus in Cell Culture

Day 3 Lecture: Yellow Fever--The Disease and Differential Diagnosis

Laboratory Diagnosis of Yellow Fever

Practical: Isolation of YF Virus in Mice

Day 4 Lecture: Yellow Fever Surveillance/Identification of YF Virus

Practical: Neutralization Test in Mice for YF Virus Identification

Day 5 Lecture: Yellow Fever Antibody Assays/Plaque Reduction Neutralization

Test for YF Antibody

Practical: Plaque Reduction Neutralization Test

Day 6 Lecture: Yellow Fever IgM Assay

Practical: Yellow Fever IgM Capture ELISA



b

Day 7 Lecture: Immunofluorescence

Practical: Identification of YF Virus by Immunofluorescence

Day 8 Lecture: Yellow Fever Vaccine--Composition, Stability and Use

Practice: Yellow Fever Vaccine Potency Test (Plaque or Mouse Test)

Day 9 Lecture: Regional Overview of Polio Fradication/AFP Surveillance/

Collection, Transportation of Faecal Specimens

Practical: Isolation of Polio Virus in Cell Culture

Day 10 Lecture: Preparation of Polio and Enterovirus Antiserum Pools

Prarctical: Microneutralization Test for Polio Virus Identification/

Microneutralization Test for Enterovirus Identification

Day 11 Lecture: OPV Potency Testing

Practical: OPV Potency Test in Cell Culture (CPE)

Day 12 Lecture: Measles Disease and Differential Diagnosis

Practical: Measles IgM Capture ELISA

Day 13 Lecture: Viral Haemaglutination and the HAI Test

Practical: HAI Test for Measles Antibody/HAI Test for Yellow Fever

Flaviviruses

Day 14 - 15 Examination and Course Evaluation

No

Annex II

Tentative Schedule of Implementation (for JFY 1996)

Middle of Sept., 1996	① Signing of Record of Discussions between the Governments of Ghana and Japan
End of Oct., 1996	② Preparation of General Information(G .I.) and Submission thereof to the Ministry of Finance and JICA Ghana Office
	③ Submission of Application Form(Al) for Japanese Expert(s) to the Embassy of Japan
Beginning of Nov., 1996	Distribution of G.I. and Application Forms to Respective Invited Governments
Beginning of Dec., 1996	(5) Receipt of Nominations from Invited Governments
Middle of Dec., 1996	 ⑤ Selection of Participants and Notification thereof to Nominating Governments ⑦ Opening of Bank Account and Notification thereof to JICA Ghana Office ⑧ Submission of Bill of Estimate to JICA Ghana Office
Beginning of Jan., 1997	Receipt of Remitted Expenses from JICA Ghana Office
February-March, 1997	COURSE IMPLEMETATION
End of March, 1997	Submission of Statement of Expenditure to JICA Chana Office
End of April, 1997	① Submission of Course Report to JICA Ghana Office



No

Annex III

II II	Tentative	Estim	nation	n of Expenses (For the F	ses the r	to be borne brinst Course)	by the Government of	Japan
ITEM OF EXPENSE			33	BREAKDOWN			AMOUNT (US\$)	REMARKS
I Invitation Expenses							28,100.00	
Air Fare (Round Trip) Per-diem Accomodation Travel Allowance Medical Insurance Prem.	888 1200 800 1000 1000 1000 1000 1000 10	USSNSS USSNSSS USSNSSSS USSNSSSS USSNSS USSNS USSNs USSNs USSNs USSNs USSNs USSNs USSNs USSNs USSNs USSNs USSNs USSNs USSNs USSNs USSns USSns USSns USSns USSns USSns USSns USSns USSns USSns USSns USSns Ussns Us Ussns Us Us Us Us Us Us	××××	10 Pax. 10 Pax. 10 Pax. 4 Pax. 10 Pax.	××	21 days 20 nights	15,000 8,200 8,000 9,000 9,000 9,000	
II Training Expenses							15.025.00	
1 Honoraria 1-1 Site Visits	. ø	SS0	×	2 places			(100.00)	
2 Employment 2-1 Secretary 2-2 Clerk 2-3 Technical Assistant 2-4 Laboratory Assistant	66 66 66 66 66 66 66 66 66 66 66 66 66	X COSS COSS COSS COSS COSS COSS COSS COS	×××				(1,050.00)	
3 Transportation 3-1 Bus Rental	@ 120	SSn		-	×	21 days	(2, 520. %)	
4 Material Procurement 4-1 Plastic Mouse Cages 4-2 Consumables 4-3 Stationery 4-4 Teaching Materials	@@@ 400 500 000	USS USS USS	×××	12 Pax. 12 Pax. 12 Pax.			(8, 880. %) 3,000. % 4,800. %	Cages will be used repeatedly. Details will be discussed later.
5 Weeting Expenses 5-1 Preparatory Meeting 5-2 Opening Ceremony 5-3 Closing Ceremony	@@@ 2010 2050	CCCC	×××	15 Pax. 50 Pax. 50 Pax.			(1, 900. °°) 150. °°) 750. °°	
6 Others 6-1 G.I. Printing 6-2 Certificate Printing 6-3 Communications		USS USS USS USS			×××	50 copies 15 copies 50 times	(575. °°) 350. °°) 75. °° 150. °°	
TOTAL							43,125.00	

Nos

APPENDIX II

A List of Attendants at the Meetings

Ghanaian Side

Prof. F. K. Nkrumah	Director, NMIMR
Dr. A. K. Nyarko	Deputy Director, NMIMR
Dr. M. Osei-Kwasi	Head of Virology Unit, NMIMR
Mr. J. Brandful	Research Fellow of Virology Unit, NMIMR
Dr. P. Addo	Head of Animal Unit, NMIMR
Mc. S. Opoku-Agyakwa	Administrative Secretary, NMIMR
Mr. Kwasi Opoku	Japan's Desk Officer, Ministry of Finance

Japanese Side

Mr. Y. Takahashi	Director, 3rd Training Division, JICA
Dr. M. Arita	Director, Dept. of Viral Diseases and Vaccine
	Control, National Institute of Health
Mr. J. Sakamoto	Advisor on International Cooperation, Ministry of
	Health and Welfare
Mr. H. Hosokawa	Senior Administrator, Training Dept., JICA
Mr. K. Abe	Assistant Resident Representative, JICA Ghana Office
Ms. Rabi Ali	Assistant Administrative Officer, JICA Ghana Office

Observers

Dr. B. Hull	Virologist, Global Programme for Vaccines and
	Immunization, WHO
Dr. O. Tomori	Virologist, WHO-AFRO



Ne

RECORD OF DISCUSSIONS BETWEEN

THE RESIDENT REPRESENTATIVE OF JICA GHANA OFFICE AND

THE AUTHORITIES CONCERNED OF THE GOVERNMENT OF THE REPUBLIC OF GHANA ON

THE THIRD COUNTRY TRAINING COURSE IN THE FIELD OF

LABORATORY DIAGNOSIS OF YELLOW FEVER AND OTHER EPI VIRAL DISEASES (POLIO AND MEASLES)

The Japanese Preliminary Survey Team, organized by the Japan International Cooperation Agency (hereinafter referred to as "JICA") and headed by Mr. Y. Takahashi, visited the Republic of Ghana between the 24th and 30th of August, 1996, had a series of discussions with the authorities concerned of the Republic of Ghana at Noguchi Memorial Institute for Medical Research, University of Ghana (hereinafter referred to as "NMIMR") with respect to the framework of a training course in the field of Laboratory Diagnosis of Yellow Fever and Other EPI Viral Diseases (Polio and Measles) under the Third Country Training Programme of JICA, and desirable measures to be taken by both Governments to ensure the successful implementation of the training course.

Based on the Minutes of Meetings concluded between the head of the Japanese Team and the director of NMIMR and subsequent dialogues, the two parties have agreed to recommend to their respective Governments the matters referred to in the documents attached hereto.

at Accra on 27th of Sept., 1996

Mr. Akio YATSUBAYASHI

Resident Representative,

JICA Ghana Office

Prof. George BENNEH Vice Chancellor,

University of Ghana

ATTACHED DOCUMENT

The Government of Japan and the Government of the Republic of Ghana will cooperate with each other in organizing a training course in the field of Laboratory Diagnosis of Yellow Fever and Other EPI Viral Diseases (Polio and Measles) for participants from African countries (hereinafter referred to as "the Course") at NMIMR under the Third Country Training Programme of JICA.

The Course will be held once a year from Japanese fiscal year 1996 to 1998, subject to an annual consultation between both Governments.

The Course will be conducted in accordance with the following;

1 TITLE

The Course is entitled "Laboratory Diagnosis of Yellow Fever and Other EPI Viral Diseases (Polio and Measles)"

2 PURPOSE

The purpose of the Course is to provide participants from African countries at risk of Yellow Fever with laboratory skills to diagnose yellow fever, polio, and measles in support of National Disease Control and Eradication Programmes.

3 OBJECTIVES

At the end of the Course, participants are expected;

- 3-1 to have gained basic knowledge and practical aspects of standard laboratory techniques for the diagnosis of yellow fever, polio, and measles,
- 3-2 to have improved their knowledge and skills in the potency testing of live viral vaccines of yellow fever, polio, and measles,
- 3-3 to have understood the regional control and eradication goals for those diseases, and the role of laboratories in achieving them.

7.

A

- 4 <u>DURATION</u>
 The first Course will be held from February 24th to March 14th, 1997.
- 5 <u>CURRICULUM</u>
 The tentative curriculum of the first Course is attached as ANNEX I.
- 6 INVITED COUNTRIES
 The Governments of the following countries will be invited to apply to the Course by nominating applicant(s);

Cameroon, Eritrea, Ethiopia, Kenya, Sierra Leone, Tanzania, Togo, Uganda and Liberia

Note: WHO may sponsor participants from countries other than those listed above.

- 7 NUMBER OF PARTICIPANTS
 The number of participants shall not exceed twelve(12) in total.
 The number of participants from invited countries and that from Ghana shall not exceed ten(10) and two(2) respectively.
- 8 <u>FACILITIES AND INSTITUTIONS</u>
 Noguchi Memorial Institute for Medical Research, University of Ghana is the venue for the Course.
- 9 QUALIFICATIONS FOR APPLICANTS
 Applicants for the Course are;
 - 9-1 to be nominated by their respective Governments in accordance with the procedure to be mentioned in the following chapter,
 - 9-2 to be engaged by the nominating Governments so that the skills obtained through the Course will be appropriately utilized on their return.
 - 9-3 to have an appropriate university qualification or advanced technical diploma,
 - 9-4 to be scientists or senior technologists in laboratories engaged in diagnostic virology and vaccine potency testing in EPI,
 - 9-5 to have practical experience of several years in microbiology and at least one year's bench experience in virology,
 - 9-6 to be under forty-five (45) years of age, as a rule,
 - 9-7 to have a good command of spoken and written English, and
 - 9-8 to be in good health both physically and mentally, to complete the Course.



10 APPLICATION PROCEDURE

- 10-1 A Government applying for the Course shall forward two (2) copies of prescribed application form for each nominee to the Government of the Republic of Ghana through diplomatic channels not later than sixty (60) days before the commencement of the Course.
- 10-2 The Government of the Republic of Ghana will inform the applying Governments through diplomatic channels whether or not the applicant(s) is/are accepted for the Course not later than thirty(30) days before the commencement of the Course.
- In organizing and implementing the Course, both Governments will take the following measures in accordance with relevant laws and regulations in force in each country. The tentative schedule of implementation for the first Course is attached as ANNEX II.
 - 11-1 The Government of the Republic of Ghana
 - 11-1-1 The Ministry of Finance:
 - (1) To forward general information brochures (G.I.) to the Governments of invited countries through diplomatic channels.
 - (2) To receive application forms and forward them to NMIMR.
 - (3) To notify the results of judgment upon applications to respective applying Governments through diplomatic channels.
 - NOTE: To facilitate the above mentioned procedures, the Government of Ghana will be supported by WHO and/or JICA when necessary.
 - 11-1-2 Noguchi Memorial Institute for Medical Research:
 - (1) To formulate the curriculum based on ANNEXI.
 - (2) To draft and print the G. I.
 - (3) To assign an adequate number of staff as instructors/research assistants to the Course.
 - (4) To provide training facilities and equipment for the Course.
 - (5) To select participants for the Course, and notify the results of the selection to the Ministry of Finance and JICA Ghana Office
 - (6) To arrange accommodation in Ghana for the participants.
 - (7) To arrange international air tickets for the participants from the invited countries and to meet and to see them off at an airport in Ghana.



R

- (8) To arrange domestic study tour(s) to be included in the Course.
- (9) To make budgetary allocations to cover the cost in conducting the Course, excluding the expenses to be borne by JICA.
- (10) To issue certificates to the participants who successfully complete the Course.
- (11) To prepare and submit a course report to the JICA Ghana Office within thirty(30) days after the termination of the Course.
- (12) To submit a statement of expenditure for the verification thereof to the JICA Ghana Office within thirty(30) days after the termination of the Course.
- (13) To coordinate any matters related to the Course implementation.

11-2 The Government of Japan:

- (1) To dispatch Japanese short-term expert(s), in accordance with the normal procedures of its technical cooperation scheme, who will support the staff of NMIMR to facilitate the implementation of the Course,
- (2) To bear the following expenses through JICA (the tentative estimate of expenses for the first Course is attached as ANNEXIII),
 - ① expenses relevant to participants from invited countries such as international economy-class flight fare, accommodation, per diem, medical insurance premium, etc.,
 - ② expenses relevant to NMIMR such as study tours, texts, teaching aids, expendable supplies, copies and reprints, secretarial services, opening and closing ceremonies, etc.
- NOTE: Technical and material support of WHO would be expected based upon discussions to be made respectively between WHO and NMIMR; and between WHO and JICA.

12 PROCEDURE FOR REMITTANCE AND EXPENDITURE

Remittance of funds for expenses to be borne by the Government of Japan and the expenditures thereof will be arranged in a following manner:

- 12-1 NMIMR will open a bank account in Ghana to receive the funds to be remitted by JICA, and inform the JICA Ghana Office of the names of the bank and the account holder and the account code number.
- 12-2 NMIMR will submit to the JICA Ghana Office a bill of estimate for the expenses to be borne by the Government of Japan not later than ninety (90) days before the commencement of the Course.
- 12-3 JICA will assess the bill of the estimate and remit the assessed amount of expenses to the account mentioned in 12-1 above not later than forty-five (45) days after the receipt of the bill of estimate.



- 12-4 NMIMR will submit to the JICA Ghana Office a statement of expenditure within thirty (30) days after the termination of the Course.
- 12-5 In case there is any unspent amount remitted by JICA, NMIMR will reimburse it to JICA in accordance with advice given by the JICA Ghana Office. The funds allocated for the flight fare, accommodation, per diem, and medical insurance premium shall not be appropriated for any other purposes.
- 12-6 When requested by JICA, NMIMR will make available for JICA's reference all the receipts and other documentary evidence to verify the expenditure stated in 12-4 above.

13 OTHERS

This attached document and the following ANNEXes attached hereto shall be deemed to be part of the Record of Discussions.

Annex I: Tentative Curriculum of the Course (for JFY 1996)

Annex II: Tentative Schedule of Implementation (for JFY 1996)

Annex III: Tentative Estimate of Expenses to be borne by the Government

of Japan (for JFY 1996)





Tentative Curriculum of the Course (for JFY 1996)

Day 1 Lecture: The Expanded Programme on Immunization: Disease Control and

Eradication Initiatives

The Role of the Laboratory in the Control and Eradication

of Diseases

Practical: Maintenance and Cryopreservation of Cell Cultures

Day 2 Lecture: Global History of Yellow Fever/Overview of Yellow Fever

in Africa

Practical: Isolation of YF Virus in Cell Culture

Day 3 Lecture: Yellow Fever--The Disease and Differential Diagnosis

Laboratory Diagnosis of Yellow Fever

Practical: Isolation of YF Virus in Mice

Day 4 Lecture: Yellow Fever Surveillance/Identification of YF Virus

Practical: Neutralization Test in Mice for YF Virus Identification

Day 5 Lecture: Yellow Fever Antibody Assays/Plaque Reduction Neutralization

Test for YF Antibody

Practical: Plague Reduction Neutralization Test

Day 6 Lecture: Yellow Fever IgM Assay

Practical: Yellow Fever IgM Capture ELISA

1.

RD

Day 7 Lecture: Immunofluorescence

Practical: Identification of YF Virus by Immunofluorescence

Day 8 Lecture: Yellow Fever Vaccine--Composition, Stability and Use

Practice: Yellow Fever Vaccine Potency Test (Plaque or Mouse Test)

Day 9 Lecture: Regional Overview of Polio Eradication/AFP Surveillance/

Collection, Transportation of Faecal Specimens

Practical: Isolation of Polio Virus in Cell Culture

Day 10 Lecture: Preparation of Polio and Enterovirus Antiserum Pools

Practical: Microneutralization Test for Polio Virus Identification/

Microneutralization Test for Enterovirus Identification

Day 11 Lecture: OPV Potency Testing

Practical: OPV Potency Test in Cell Culture (CPE)

Day 12 Lecture: Measles Disease and Differential Diagnosis

Practical: Measles IgM Capture ELISA

Day 13 Lecture: Viral Haemaglutination and the HAI Test

Practical: HAI Test for Measles Antibody/HAI Test for Yellow Fever

Flaviviruses

Day 14 - 15 Examination and Course Evaluation

Annex II

Tentative Schedule of Implementation (for JFY 1996)

Middle of Sept., 1996 ① Signing of Record of Discussions between the Governments of Ghana and Japan

End of Oct., 1996 ② Preparation of General Information(G.I.) and
Submission thereof to the Ministry of Finance and
JICA Ghana Office

③ Submission of Application Form(Al) for Japanese Expert(s) to the Embassy of Japan

Beginning of Dec., 1996 ⑤ Receipt of Nominations from Invited Governments

Middle of Dec., 1996 © Selection of Participants and Notification thereof to Nominating Governments

⑦ Opening of Bank Account and Notification thereof to JICA Ghana Office

(8) Submission of Bill of Estimate to JICA Ghana Office

February-March, 1997 COURSE IMPLEMETATION

End of April, 1997 (D) Submission of Course Report to JICA Ghana Office

AV

1

Annex

utive Estimation of Expenses to be borne by the Government of Japan (For the First Course)	BREAKDOWN AMOUNT (US\$) REMARKS	28,100.00	.500 US\$ × 10 Pax. × 21 days 4,200.	0 Pax. X 20 nights 4 Pax. 0 Pax.	15,025.00	50 US\$ × 2 places 100.00	150 US\$ X 1 Pax. 75 US\$ X 2 Pax. 150 US\$ X 5 Pax. 75 US\$ X 5 Pax. 75 US\$ X 750.00	120 US\$ × 21 days 2,520.00	400 US\$ × 12 Pax. 50 US\$ × 12 Pax. 4,800.00 50 US\$ × 12 Pax. 4,800.00 600.00 400 US\$ × 12 Pax. 4,800.00 600.00 600.00	10 US\$ × 15 Pax. 15 US\$ × 50 Pax. 20 US\$ × 50 Pax. 1,000.00	SSS
Estimation	BREAK		20 US\$	90 USS X X X X X X X X X X X X X X X X X X		us\$ ×	XXX XXXX XXX	20	00 US\$ X X 122 40 US\$ X X 122	USS USS XXX XXX SOO SOO SOO SOO SOO SOO SOO S	2000 CO S S S S S S S S S S S S S S S S S S
Tentative			പ് തുക	മ മര		@	®®®®	®	@@@ 4	ക മു	ବ୍ରଉପ
Annex III	ITEM OF EXPENSE	I Invitation Expenses		3 Accomodation 4 Travel Allowance 5 Medical Insurance Prem.	II Training Expenses	1 Honoraria 1-1 Site Visits	2 Employment 2-1 Secretary 2-2 Clork 2-3 Technical Assistant 2-4 Laboratory Assistant	3 Transportation 3-1 Bus Rental	4 Material Procurement 4-1 Plastic Mouse Cages 4-2 Consumables 4-3 Stationery 4-4 Teaching Materials	5 Meeting Expenses 5-1 Preparatory Meeting 5-2 Opening Ceremony 5-3 Closing Ceremony	6 Others 6-1 G.I. Printing 6-2 Certificate Printing 6-3 Communications

Alb

FACSIMILE MESSAGE

October 16th, 1996

From: Yoshiyuki TAKAHASHI
Director, 3rd Training Div.,
Japan Int. Cooperation Agency
Tel. 81-03-5352-5145/6/7/8
Fax. 81-03-5352-5018/9

To: Dr. Barbara HULL
Global Programme for Vaccine
and Immunization,
World Health Organization
Tel. 41-22-791-4405
Fax. 41-22-791-0746

Re: Yellow Fever/Polio Training Course in Ghana

Dear Dr. Hull,

I am pleased to inform you that the Record of Discussions on the captioned training course was duly signed between both governments of Ghana and Japan as attached herewith. After coming back to Japan, we concluded to include Liberia as one of the invited countries to the course on JICA's expenses.

Now, as we discussed and agreed upon in Geneva and Accra, I would like you to take necessary measures for the provision of technical inputs of WHO, which is undoubtedly a crucial step to a successful course implementation.

It is highly appreciated if you accordingly provide us with a letter confirming WHO contribution to the course for our further ease.

With best regards

WORLD HEALTH ORGANIZATION



ORGANISATION MONDIALE DE LA SANTE

Direct Téléphone: Facsimile direct: GPV Internet address: Internet Address In reply please refer to: 41 (22) 791 4798/4804 41 (22) 791 4889/4192 GPV@who.ch leejw@who.ch Mr Yoshiyuki Takahashi Director, Third Training Division Japan International Cooperation Agency Shinjuku-Mitsui Bld, 2-1-1 Nishi-Shinjuku Shinjuku-ku, Tokyo 162-04 Japan

12 December 1996

Dear Mr Takahashi,

Thank you for the Record of Discussions between the governments of Ghana and Japan on the training courses on "Laboratory Diagnosis of Yellow Fever and other EPI Viral Diseases (Polio and Measles)," which are to be held in Ghana in 1997 to 1999.

It was proposed during your visit to visit to Geneva in August, 1996, and during discussions at the Noguchi Institute in Accra, that the World Health Organization should provide the following:

- 1. Two facilitators for each course
- 2. Training manuals and technical protocols
- 3. Reference reagents (cell cultures, antigens and antisera).

I hereby confirm this contribution and look forward to a successful collaboration.

Yours sincerely,

Dr J. W. Lee.

Director

Global Programme for Vaccines and

Immunization

GENERAL INFORMATION

A. INFORMATION

A.1 Rationale

In 1989, the Noguchi Memorial Institute for Medical Research (NMIMR), Legon, Ghana, was nominated by the WHO as a collaborating laboratory in support of EPI. In that capacity and for the purpose of polio eradication in the African Region, the Institute, from 1991 to 1996, provided training for staff from other laboratories in the Region in polio diagonsis and vaccine potency testing. At the conclusion of the programme, it was agreed by participating sponsors, WHO and JICA, that a new training course in "Laboratory Diagnosis of Yellow Fever and EPI ViralDiseases (Polio and Measles)" be conducted at the NMIMR for participants from African countries.

A.2 Title

The title of the Course is "Laboratory Diagnosis of Yellow Fever (YF), and Other EPI Viral Diseases (Polio and Measles)".

A.3 Aims

The purpose of the Course is primarily to provide participants from African countries with the opportunity of upgrading relevant techniques and knowledge in laboratory diagnosis of Yellow Fever (YF), and other EPI viral diseases (Polio and Measles); and to make such capability accessible to every African country.

A.4. Objectives

At the end of the Course, participants are expected to:

- (1) Have the basic knowledge and application of standard techniques and procedures in laboratories supporting the Expanded Programme on Immunization (EPI).
- (2) Improve their knowledge and techniques in the laboratory diagnosis of YF, Polio and Measles, as well as potency testing for YF, Polio and Measles vaccines.
- (3) Support National and Regional Disease Control and Eradication Programmes.

A.5 Duration

February 24 to March 14, 1997.

A.6 Training Institute

Noguchi Memorial Institute for Medical Research (NMIMR). University of Ghana, Legon, Ghana

A.7. Curriculum

The Course Curriculum is attached as Annex 1.

A.8. Methodology

The Course will be conducted in the form of lectures and practical sessions in diagnostic techniques and vaccine potency testing procedures for YF, Polio and Measles.

A.9 Language

The Course will be conducted in English.

A.10 Certificate

Certificates will be awarded to participants who successfully complete the Course.

B. APPLICATION INFORMATION

B.1 Qualification of Applicants

Applicants for the Course are:

- (1) to be nominated by their respective Governments in accordance with the procedure to be mentioned in the following chapter,
- (2) to be engaged by the nominating Governments so that the skills obtained through the Course will be appropriately utilized on their return,
- (3) to have an appropriate University qualification or advanced technical diploma,
- (4) to be scientisits or senior technologists in laboratories engaged in diagnostic virology and vaccine potency testing in EPI,
- (5) to have practical experience of several years in microbiology and at least one year's bench experience in virology,
- (6) to be under forty-five years (45) years of age, as a rule,
- (7) to have a good command of spoken and written English, and
- (8) to be in good health both physically and mentally, to complete the Course.

B.2 Procedure for Application

(1) A government desiring to nominate applicant(s for the course should fill in and forward one copy of nomination forms for each applicant to the International Economic Relations Division, Ministry of Finance, P.O. Box M.40, Accra and one copy to the Director, Noguchi Memorial Institute for Medical Research, University of Ghana, P.O. Box 25, Legon, Ghana, not later than 1st December each year. It will be helpful that the WHO-country office is informed of the nimination(s).

1. . . .

(2) The Government of Ghana in conjunction with NMIMR will inform the applying Government whether or not the nominee's application has been accepted not later than mid-December each year.

B.3 Country Report

Participants are requested to prepare a report of their respective countries on:

- (1) the present situation in their field of study and interest,
- (2) the status of (disease) surveillance for YF, Polio and Measles (including number of cases and vaccination coverage for previous year).
- (3) the role of participant's laboratory in the diagnosis of YF, Polio and Measles.
- (4) the relationship between the laboratory and the National EPI Programme.

It is important for participants to contact the national EPI authority in preparing the Country Report.

Country Reports should be typewritten in accordance with the attached form (Annex II) and submitted to NMIMR on arrival in Ghana.

Country Reports will be used during the Course for training and assessment of participants.

C. ALLOWANCES AND EXPENSES:

The following expenses in accordance with JICA and NMIMR rules and regulations will be covered for each participant:

- (1) Return air-ticket (normal economy fare) between the international airport designated by Accra.
- (2) Free accommodation in addition to an allowance of 20 US\$ per day as pocket money.
- (3) Medical insurance premium.
- (4) Expenses for study tours.

D. REGULATIONS

Participants are required:

- (1) To observe strictly the course schedule and not to change training subject.
- (2) Not to extend the training period.
- (3) Not to bring any member of their family.
- (4) To return to their home country on completion of the course according to the travel schedule designated by NMIMR.

- (5) To carry out such instructions and abide by such conditions as may be stipulated by both the nominating government and the Ghana Government in respect of the training.
- (6) To observe the rules and regulations of the training institution or establishment in which participants undertake study or training.
- (7) To refrain from engaging in political activities, or any form of employment for profit or gain.
- (8) To discontinue the course, should they fall seriously ill and be considered unable to continue the training or commit an improper act.

OTHERS

(1) Preliminary Instruction:

Participants are requested to report in person to the local IICA Office or in the absence of IICA Office, WHO country office in their own country in order to complete the necessary procedures and obtain pre-departure instructions.

(2) Visa:

Before leaving their country, participants should obtain a visa for entry to Ghana which will be issued by the diplomatic missions of Ghana in their countries. Where there is no Ghana Embassy, the Noguchi Institute (NMIMR) could be informed early enough to arrange for a visa on arrival in Ghana.

(3) Air-ticket:

Participants are requested to arrive in and leave Ghana on the date designated by NMIMR. The date will be finally confirmed by the air-ticket sent to the participants. Participants who receive the air-ticket but are unable to travel are obliged to return the ticket or refund its value to NMIMR.

(4) Photograph:

For administration purposes, participants are requested to bring five (5) copies of a recent photograph (passport size).

(5) Airport:

On arrival at the Kotoka International Airport, Accra, participants are requested to note the following arrival procedues:

- (1) When immigration and customs clearance procedures have been completed, participants should proceed to the exit and look for NMIMR staff who will page participant's name and country.
- (2) NMIMR'staff will guide participants to their hotels.

(6) Correspondence:

For inquiries and further information please contact local JICA office or WHO country office. In case of difficulty, address correspondence to:

The Director,
N.M.I.M.R.,
University of Ghana,
P.O. Box 25,
Legon,
Ghana.

Tel: No. 233-21-500374, 501180, 501178, 501179

Fax No. 233-21-502182 InternetNo. Noguchi @ncs.com.gh.

ANNEX 1

TENTATIVE CURICULUM OF THE COURSE (FOR JFY 1996)

Day 1 - Lecture : The Expanded Programme on Immunization:

Disease Control and Eradication Initiatives.

The Role of the Laboratory in the Control and

Eradication of Diseases.

Practical: Maintenance and Cryopreservation of Cell

Cultures.

Day 2 - Lecture : Global History of Yellow Fever/Overview of

Yellow Fever in Africa.

Practical : Isolation of YF Virus in Cell Culture.

Day 3 - Lecture : Yellow Fever -- The Disease and Differential

Diagnosis - Laboratory Diagnosis of

Yellow Fever.

Practical : Isolation of YF Virus in Mice

Day 4 - Lecture : Yellow Fever Surveillance/Identification of

YF Virus.

Practical: Neutralization Test in Mice for YF Virus

Identification.

Day 5 - Lecture : Yellow Fever Antibody Assays/Plaque

Reduction Neutralization Test for YF Antibody.

Practical: Plaque Reduction Neutralization Test.

Day 6 - Lecture : Yellow Fever IgM Assay

Practical: Yellow Fever IgM Capture ELISA.

Day 7	•	Lecture	:	Immunofhorescence
		Practical	:	Identification of YF Virus by Immuno-fluorescence.
Day 8	-	Lecture	:	Yellow Fever Vaccine Composition, Stability and Use.
		Practical	:	Yellow Fever Vaccine Potency Test (Plaque or Mouse Test).
Day 9	-	Lecture	:	Regional Overview of the Polio Eradication/AFP Surveillance/Collection, Transportation of Faecal Specimens.
		Practical	:	Isolation of Polio Virus in Cell Culture.
Day 10	. •	Lecture	:	Preparation of Polio and Enterovirus Anti-serum Pools.
	. •	Practical	:	Micronentralization Test for Polio Virus Identification/Microneutralization Test for Enterovirus Identification.
Day 11	- ,	Lecture	:	OPV Potency Testing.
		Practical	:.	OPV Potency Test in Cell Culture (CPE).
Day 12	•	Lecture	:	Measles Disease and Differential Diagnosis.
		Practical	:	Measles IgM Capture ELISA.
Day 13		Lecture		Yiral Haemaghitination and the HAI Test.
· .		Practical	:	HAI Test for Measles Antibody-HAI Test for Yellow Fever Flaviviruses.
Day 14	-	Examination	n an	d Course Evaluation.

COUNTRY REPORT

ON

LABORATORY DIAGNOSIS OF YELLOW FEVER

AND

OTHER EPI RIVAL DISEASES (POLIO AND MEASLES)

1.	Name of Country	-4 	
2.	Name of Particip	ant:	
3.	Name of Organiz	ation:	
4	Organization Cha	·	·
	A. Present situati Procedures;	ion of Vaccine Potency	Testing and Polio Diagnostic
	B. Services of th	e Organization.	
	C. Your present	position indicated in the Org	anization chart.
	D. Job in detail in	the organization.	
5.		of Cases And Vaccine Cov	C .
	DISEASE	NUMBER OF CASES	VACCINATION COVERAGE*
	YELLOW FEVER		

POLIO

MEASLES

6. Role Of Your Laboratory In Surveillance And Diagnosis of Diseases, Especially Yellow Fever, Polio and Measles.

^{*} SPECIFY AGE GROUP VACCINATED.

for a course in "Laboratory Diagnosis of Yellow Fever (YF), and Other EPI Viral Diseases (Polio and Measles)" from the 24th February -14th March 1997 at the Noguchi Memorial Institute for Medical Research (NMIMR), University of Ghana in co-operation with JICA and WHO. a. All information supplied by the nominee are complete and certifies that and correct. b. Nominee is a university graduate, or has the equivalent academic background. c. Nominee is presently working for a laboratory at the national level which functions in support of EPI either in vaccine production, quality control, potency testing or polio diagnostics. d. Nominee has practical experience of several years in the related field. Nominee is under forty-five (45) years of age. f. Nominee has a good command of spoken and written English, and g. Nominee is in good health, both physically and mentally, to complete the course.

Discussion document

A framework for CONTROL OF YELLOW FEVER IN AFRICA April, 1996

Global Programme for Vaccines and Immunization in association with the Division of Emerging and other Communicable Diseases
World Health Organization

SUMMARY

During the past four years there has been a dramatic resurgence of yellow fever in Africa. The number of cases is probably greater now than before systematic immunization started in the 1930s. Though yellow fever is generally a rural disease associated with forest areas the threat to urban areas in Africa is increasing. During 1995, for example, cases of yellow fever have been confirmed in Monrovia and other urban areas of Liberia, causing a significant epidemic threat.

During the past 10 years, all 33 countries at risk of yellow fever have built extensive immunization services and are now able to support the introduction of routine infant yellow fever immunization and planned mass campaigns. Furthermore, the Global Advisory Group of the Expanded Programme on Immunization recommended that yellow fever vaccine be added to routine immunization programmes. (see attached EPI update - March 1992)

With external financial support yellow fever can be controlled in Africa within five years using four complementary strategies:

- Surveillance
- Outbreak prevention
- Outbreak response
- Routine immunization

External support needed in millions of US dollars (excluding outbreak response) over a five year period:

 Campaign
 145 195 669

 Routine
 48 124 974


 Surveillance
 231 650

These sums are based on the need for coverage of all 33 countries. Individual countries or groups of countries can be selected for support. These funds are needed for vaccine procurement, national support and technical assistance. Thus funds can be transferred to a procurement agency for example UNICEF, directly to the country or countries selected, or to WHO.

Approximately 35% of the funds are needed in the countries and can be provided directly.

Over 50% of the funds are assigned for vaccine procurement. (Two of the world's major yellow fever vaccine manufacturers are located in the European Union).

Approximately 15% of the funds are needed for technical assistance.



In the absence of routine immunization and planned campaigns, the cost of outbreak control could exceed US\$5 million each year for the coming five years and beyond.

BACKGROUND

THE DISEASE

Yellow fever is an acute infectious disease characterized by sudden onset of fever, chills, head, back and muscle pain, nausea and vomiting. These may progress to jaundice and haemorrhagic signs. Death usually occurs 7-10 days after onset of illness, following a period of remission on the third or fourth day. During epidemics, the case fatality rate for unimmunized adults may exceed 50%, and for children 70%.

The agent which causes yellow fever is a mosquito-borne virus which is involved in two transmission cycles. In "jungle" yellow fever, transmission occurs between forest-dwelling mosquitoes and non-human primates, while in the "urban" cycle transmission is between domestic mosquito species, especially Aedes aegypti, and man. Humans may acquire the infection through the bite of an infected jungle mosquito and may return to an urban area where they become ill 3 to 6 days later. An Aedes mosquito feeding on such a person may initiate an outbreak of urban yellow fever.

STATUS

A total of 21,661 cases of yellow fever were reported from Africa during 1986 to 1995. However, epidemiological studies have shown that this is a greatly under-reported disease, and have estimated the true incidence to be ten times this figure. The spread of yellow fever from settlements on the fringe of the jungle is related to the growth of large urban communities which favor the proliferation of Aedes mosquitoes. The combination of poor immunization levels and rapid urbanization present ideal conditions for the development of explosive epidemics. The most recent of these occurred in Liberia in 1995, where the 360 reported cases probably are a small fraction of the true number and where patients with yellow fever were hospitalized in Monrovia and Buchanan, urban areas where few people have been exposed to the virus previously.

Extensive use of yellow fever vaccine in French west Africa from 1939 to 1952 resulted in a sharp decline in incidence in these countries. This was given by scarification together with smallpox vaccine, and was discontinued with the eradication of smallpox. Manufacture of the French Neurotropic vaccine used was discontinued in 1980. A resurgence of yellow fever followed, resulting in epidemics during the 1990's with over 25% of cases occurring in children less than 5 years old.

The presently used vaccine, based on the 17D strain, meets strict WHO requirements of safety and is one of the most effective vaccines, resulting in the development of long lasting antibody in 95% or more of recipients. It is recommended for use in children over 6 months of age.

Immunization coverage in Africa remains low and yellow fever has re-emerged, after more than 10 years of absence, in Kenya (1992), Ghana (1993), Gabon (1994) and Liberia (1995). It will continue to produce expensive and disruptive epidemics and menace urban areas unless there is a concerted effort to anticipate and prevent them through a long term programme of surveillance and immunization.

Yellow fever vaccine is currently manufactured at the Institut Pasteur, Senegal. Its production capacity is in excess of 15 million doses each year.

COUNTRIES AT RISK IN AFRICA

Yellow fever is endemic in 33 countries of equatorial Africa shown on the attached map. Their combined population is 468 million. Immunization services and disease reporting systems are well established, and all countries are committed to the goals of measles reduction and polio eradication by the year 2000. Many will be conducting national immunization days with oral polio vaccine during 1996 and 1997. Improvement in disease surveillance is expected to follow, and to be

World Health Organization

sustainable. Linking yellow fever to the planned polio and measles activities could prevent major yellow fever epidemics and save thousands of lives each year after 1997.

STRATEGIES

Four strategies, implemented concurrently, have the potential to bring yellow fever fully under control in Africa.

- A Surveillance
- B Outbreak prevention
- C Outbreak response
- D Routine immunization

These four strategies and the associated activities are described in detail below.

A SURVEILLANCE

A continuing, sensitive system of surveillance is essential in all at-risk countries for the early detection of cases which will permit rapid action to contain an outbreak. Even in countries which have instituted preventive measures, vigilance is needed to detect spread of the virus from its jungle reservoirs to the human population. The task of identifying an early, isolated case before it triggers an epidemic is made more difficult by the need to distinguish yellow fever from diseases with similar symptoms such as hepatitis, malaria and other febrile jaundice. Laboratories capable of differential diagnosis are essential.

Following the identification of a focus of virus activity in the Kerio Valley in Kenya in 1992-1993, a system of active surveillance was set up by EPI and CDS, the predecessor of EMC based on selected health facilities around the area. This has detected continuing activity through 1995. These findings highlight the feasibility of comprehensive surveillance and follow-up action in all 33 African countries at risk.

The Expanded Programme on Immunization has an extensive surveillance system that covers all EPI vaccine preventable diseases, and in collaboration with the Division of Emerging and other Communicable diseases (EMC) this system includes yellow fever. The system is highly effective for some diseases but less so for yellow fever. Investment in surveillance will help to ensure that the funds out into immunization are well monitored and managed.

ACTIVITIES

- 1. Develop guidelines on case detection and investigation, data collection and management, specimen collection and transport
- 2. Conduct awareness and planning seminars for medical and laboratory personnel
- 3. Train field staff and laboratory personnel in selected reference laboratories
- 4. Procure supplies for specimen collection and transport
- 5. Procure laboratory reagents
- 6. Identify resources for follow-up action

B OUTBREAK PREVENTION

An individual of any age who has not been immunized or had a natural infection is susceptible to yellow fever. The success of immunization in west Africa in the 40's and 50's highlights the effectiveness of achieving high coverage of the population. Although a yellow fever vaccination certificate is valid for only 10 years under the International Health Regulations, antibodies persist for

World Health Organization

a much longer time, probably for life. Mass campaigns are needed in the countries at risk on a onetime basis for urban populations and villages at risk close to forests. The figures in this proposal are based on 50% of the population being at risk, and would have to be adjusted based on individual country estimates.

ACTIVITIES

- 1. Identify funding for vaccines, syringes and operations
- 2. Decide on timing and coordination with other campaigns
- 3. Plan publicity, logistics and cold chain
- 4. Identify and train staff
- 5. Immunize
- 6. Review progress and problems

C OUTBREAK RESPONSE

Measures to control epidemics of yellow fever have been hampered by the late recognition and reporting of the disease. In Africa, delays of two months or more are not uncommon between epidemics and their recognition. This is due in part to the occurrence of the earliest cases in remote areas with few medical services and the unfamiliarity of medical personnel with the disease. Another factor is the occurrence of other diseases such as viral hepatitis, malaria and leptospirosis which may be clinically confused with yellow fever, and the lack of laboratory capability in many countries for confirming the diagnosis.

Appropriate responses to the report of a possible outbreak include collection and testing of specimens, epidemic investigation to determine the scope of the outbreak, emergency vaccination of at-risk populations, entomological investigation and vector control, and institution of measures to prevent spread of virus from patients to mosquitoes.

ACTIVITIES

- 1. Initiate epidemiological investigation
- Collect blood samples from febrile cases and send to nearest competent virological laboratory
- 3. Arrange for emergency supplies of vaccine
- 4. Vaccinate at-risk groups
- 5. Conduct entomological investigation
- 6. Begin vector control operations in affected urban areas
- 7. Instruct health facilities in transmission control
- 8. Extend mass vaccination

D ROUTINE IMMUNIZATION

The incorporation of yellow fever vaccine into the routine EPI was recommended in 1988 by a joint WHO/UNICEF Technical Group on Immunization in Africa. It was suggested that this be done at the visit for measles immunization at 9 to 12 months of age, thus avoiding the need for an additional visit. To date 16 of the 33 at-risk countries report coverage by the first birthday. Coverage levels in 1994 ranged from less than 1% in Mali to 87% in the Gambia. Only four countries achieved over 45% yellow fever vaccine coverage in infants. Many of the countries which have not begun infant immunization or which show low coverage are among the poc.est, and the cost of yellow fever vaccine (0.18 USD per dose) is a major obstacle to achieving high coverage.

World Health Organization

In the Gambia, yellow fever was added to the EPI in 1979 following a successful mass campaign in which 97% of the population over 6 months of age received a dose. There have been no subsequent reports of yellow fever from that country. Analysis of the cost of this intervention showed that the addition of yellow fever did not significantly increase the per dose cost of vaccines delivered in the EPI.

ACTIVITIES

- 1. Estimate annual population of children surviving to 9 months
- 2. Identify funds for vaccine, syringes and additional service costs
- 3. Train staff at immunization centers
- 4. Add yellow fever to immunization cards
- 5. Educate mothers/guardians
- 6. Routine review of progress and constraints

FUNDING

The table that follows is a five-year summary, by country and by activity, of the expected funding requirements in US dollars.

These figures are entirely consistent with a plan for yellow fever control prepared by the African Regional Office of WHO as part of their plan of action for al EPI diseases in Africa for the 1990s. An extract is attached as one annex.

The supplementary resources needed are also listed at the end of the table. These resources are in support of the following activities and supplies:

Strategy A - Surveillance

- · YF surveillance guides, English and French
- Forms
- Information seminars for District medical staff
- Training for field staff collecting data and specimens
- Training in laboratory diagnosis
- Reagents and supplies
- Vaccine for response

Strategy B - Outbreak prevention

- Vaccine
- Syringes
- Cold chain equipment
- Operational costs
- Public mobilization

Strategy C - Outbreak response

- Vaccine (Stockpiles for emergency use).
- Syringes
- Extra cold chain equipment
- Operational costs
- Personnel (consultants)
- Insecticide and spraying equipment
- Clean-up campaign/mosquito nets

Strategy D - Routine immunization

- Vaccine, routine through UNICEF
- Additional service costs
- Training of EPI field staff
- Vaccination cards
- Public education (lower key than B)

Costs of Campaigns - Yellow Fever

Table Total Table Total Table Total Table Total Tota	Countries				Vaccino			Transport	selections.		Training	-			
Columbia	Financially Dependant	Total Population	Target population 70%	Vaccine cost	Syringe Cost	Cold Box Cost	Airfreight Vaccines	Airfroight Syringes	Local Transport	Materials	Publicity	Workshop	Project Manager	Misc	Total
Columbs	Benin	5 574 000	3 901 800			41 359	109 602	45 495	100001	5 650	10 000	2 000	29.042	000	678 879
\$5.500 4.000 4.000 1.200 1.200 1.200 1.000 1.2	Burkina Faso	10 593 000	7 415 100			78 600	208 290	86 460	10 000	9 040	10 000	l	29 042		2 178 247
11 13 13 13 13 13 13 13	Burundi	6 578 000	4 504 500			48 809	129 343	53 690	10 000	5 650	10 000	i	29 042		1 970 115
115 100 20 20 20 20 20 20 2	A S	3 397 000	2 377 900			25 206	66 795	27 726	5 000	4 520	2 000		29 042		3 036 106
11 11 11 11 12 12 13 13	Chad	e 543 000	4 580 100	-	- [48 549	128 655	53 404	10 000	5 650	000 01	2 200	29 042	9	1 959 960
11 135 2000 6.056 6.00 6.00 7.0	Equatorial Guinea	410 000	287 000		ı	3 042	8 062	3 346	5 000	2 260	2 000	2 000	29 042	9000	167 262
11 15 15 15 15 15 15 15	Ethiopia	56 713 000	39 699 100		3 934 578	420 810	1 115 148	462 892	10 000	37 290	10 000	2 000	29 042	2 000	15 K47 NO
1970 00 1.856 00 1.256 00 1.256 00 1.256 00 1.257 00 1.257 00 1.257 00 1.257 00 1.0000 1.	Gambua	1 155 000	808 500		80 130	8 570	22 711	9 427	2000	2 260	2 000	2 000	250 042	000	187 187
68.000 48.22 10.0	Ghana	17 972 000	12 580 400		1 246 843	133 352	353 383	146 687	10 000	13 560	10 000	2 000	29 042	200	363 696 3
1966 600 2198 600 26 4025 91 270 20 28 50 27 50 20 29 50 20 50 0 20	Cuinea	6 903 000	4 832 100	•		51 220	135 734	56 342	10 000	5 650	10 000		20 075	3 6	2000000
23-137 (200 2.198-90) 5 6446 914 2 2021 439 275 077 275 416 2021 420 5 570 5 570 5 570 5 5 50 5 5 5 5 5 5 5	Guinea-Bissau	1 096 000	767 200			8 132	21 551	8 946	\$ 000	2 260	2 000		20 042	3 8	AUG 920
31 to 00 21 to 00 21 to 00 2	Келуа	29 137 000	20 395 900	5 404 914		2:6 197	572 921	237 816	10 000	20 340	1000	000	20 072	3 8	277 000
11134 000 7733 800 2 605 357 772 444 25 614 218 229 90 876 10 000 9 040 10 000 2 000 25 042 5 000 233 000 6 625 300 1755 738 656 655 70 201 161 140 175 73 10 000 2 10 00 2 000 2 000 2 000 24 050 000 571 200 1 135 800 2 65 655 70 201 161 405 1 132 1 46 574 1 134 1 46 574 1 134 1 46 574 1 134 1 24 65 000 5 71 200 1 135 800 2 25 8 80 2 25 8 1 2 25 8 1 2 25 8 2 25 8 2 25 8 25 000 2 25 1 200 2 200 2 200 2 200 2 200 2 200 25 000 2 25 1 200 2 200 2 200 2 200 2 200 25 000 2 25 1 200 2 200 2 200 2 200 2 200 25 000 2 25 1 200 2 200 2 200 2 200 2 200 25 000 2 25 1 200 2 200 2 200 2 200 25 000 2 25 1 200 2 200 2 200 2 200 25 000 2 25 1 200 2 200 2 200 2 200 25 000 2 200 2 200 2 200 2 200 25 000 2 200 2 200 2 200 2 200 25 000 2 200 2 200 2 200 25 000 2 200 2 200 2 200 25 000 2 200 2 200 2 200 25 0	Libena	3 140 000	2 198 000	582 470		23 299	61 742	25 629	\$ 000	3 390	80,5	2 000	20 07	200	100 870 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
13 000 1533 100 1633 100 1733 12 161 873 1733 11 151 872 19 042 5 000 2 350 5 000 2 00	Mali	11 134 000	7 793 800	2 065 357		82 614	218 928	90 876	10 000	9 040	10 000	2 000	20000	3 8	2 206 200
9 465 000 6 625 500 1 1515 500 566 653 70 230 185 110 177253 10 000 7 7 910 10 000 1 2	Mauritania	2 333 000	1 633 100	432 772		17 311	45 874	19 042	2 000	3 390	2000	2 000	29 042	200	706 267
Street	Niger	9 465 000	6 625 500	1 755 758	656 653	70 230	186 110	77 253	10 000	7 910	10 000		20000	200	707 077
Columb	Rwanda	8 150 000	5 712 000		566 116	60 547	160 450	66 602	10 000	6 780	000 01		2000	200	CA SOO 7
Column	Sao Tomé & Principe	135 000	94 500		990 6	1 002	2 655	1 102	5 0003	2 2601	000 \$	000 0	2000	300	27.20
9 444 000 6 658 600 1 759 222 653 1 70 371 186 484 77 4 20 10 000 7 9 10 000 2 0 00 2 0 00 2 0 0 0 0 0 0 0 0	Sierra Leone	4 617 000	3 231 900	856 454	320 314	34 258	90 784	37 684	2 000	4 520	2 000	2000	2007	3 8	00, 400
28 855 000 20 189 500 5 352 863 2 100 1673 2 14 104 5 60 479 2 26 5176 2 2	Somalia	9 484 000	6 638 800	1 759 282	657 971	70 371	186 484)	77 408	10 000	7 910	1000	000	2000	3 8	000 000 0
30 556 000 21 375 200 5 664 428 2 116 496 226 5/77 600 423 249 235 10 000 21 4/0 10 000 2 000 2 9 042 5 000 2	Sudan	28 855 000	20 198 500	5 352 603		214 104	567 376	235 515	10 000	20 340	0000	2002	2000		604 610 7
4 269 000 2 988 300 731 900 296 170 31 676 83 941 34 844 5 000 4 520 5 000 2 9042 5 000 2 96 20	Tanzania	30 536 000	21 375 200	5 664 428		226 577	600 429	249 235	10 000	21 470	000 01	200	250 000		0 44/ 852
13 630 000 15 374 100 2 127 500 2 135 285 890 360 179 262 10 000 15 820 10 000 2 0	Togo	4 269 000	2 988 300	791 900	1	31 676	83 941	¥ 84 48	2 80	4 520	2 000	1000	29 042	3 8	7 200 000
y independent countries 45 281 000 31 696 700 8 53 965 3 141 460 335 985 890 360 368 584 10 000 30 510 10 000 2	Uganda	21 963 000	15 374 100	4 074 137	1 523 727	162 965	431 858	179 262	10 000	15 820	100001	2 000	29 042	3 8	CEO 607
vindependent countries 11 469 000 8 028 300 2 127 500 795 685 65 100 225 515 93 610 10 000 9 040 10 000 2 000 29 042 5 000 on 13 609 000 9 526 300 2 524 470 944 152 100 979 267 554 111 077 10 000 10 170 10 000 2 000 2 000 2 9 042 5 000 order 403 000 2 82 100 74 757 27 959 7 924 3 289 5 000 2 260 5 000 2 000 </td <td>Zaire</td> <td>45 281 000</td> <td>31 696 700</td> <td>8 399 626</td> <td>3 141 460</td> <td>335 985</td> <td>890 360</td> <td>369 584</td> <td>10 00</td> <td>30 510</td> <td>000 01</td> <td>2 000</td> <td>29 042</td> <td>9 000</td> <td>13 223 856</td>	Zaire	45 281 000	31 696 700	8 399 626	3 141 460	335 985	890 360	369 584	10 00	30 510	000 01	2 000	29 042	9 000	13 223 856
on 11 469 000 8 028 300 2 127 500 795 685 85 100 225 515 93 610 10 000 9 040 10 000 2 000 2 000 2 9 042 5 000 on 13 609 000 9 526 300 2 524 470 944 152 100 979 267 554 11 1077 10 000 10 170 10 000 2 000 <td>Partially independent</td> <td>Countries</td> <td></td> <td>-</td> <td></td>	Partially independent	Countries		-											
on 13 609 000 9 £26 300 2 £24 470 944 152 10 70 10 000 10 000 2 000 <td>Angola</td> <td>11 469 000</td> <td>8 028 300</td> <td>2 127 500</td> <td>795 685</td> <td>85 100</td> <td>1252 200</td> <td>1013 60</td> <td>000</td> <td>0.00</td> <td></td> <td></td> <td></td> <td></td> <td></td>	Angola	11 469 000	8 028 300	2 127 500	795 685	85 100	1252 200	1013 60	000	0.00					
cride 403 000 282 100 74 757 27 359 2 990 2 1 85 5 000 2 260 5 000 2 260 5 000 2 9042 5 000 volie 14 733 000 1 865 500 49 358 1 9 74 2 2 402 2 1 752 5 000 2 300 2 0	Cameroon	13 609 000	9 526 300	2 524 470	944 152	100 979	257 504	144 077	2 6	000	0000	2 000	29 042	2000	3 392 491
2 665 000 1 865 500 494 358 144 890 19 774 52 402 21 752 5000 3 390 5 000 2 000 29 042 5 000 voire 14 733 000 10 313 100 2 732 972 1 022 131 109 319 289 695 120 251 10 000 11 300 10 000 2 000 29 042 5 000 115 020 000 80 514 000 2 1 336 210 7 979 743 853 449 2 261 628 938 793 10 000 74 580 10 000 2 000 2 9 042 5 000 2 8 532 000 5 972 400 15 82 886 591 925 63 307 167 765 65 656 10 000 6 78 10 000 2 000 2 9 042 5 000 2 9	Cape Vorde	403 000	282 100	74 757	27 959	060	7 924	1 280	3 6	0/10/	200	2 000	29 042	8	4 014 482
voire 14 733 000 10 313 100 2 732 972 1 022 131 109 319 28 655 120 251 10 000 1 300 10 000 2 000 2 0 02 2 0 02 5 000 115 020 000 80 514 000 21 336 210 7 979 743 853 448 2 261 638 938 793 10 000 74 580 10 000 2 000 2 000 29 042 5 000 281 025 000 8 532 000 1 582 686 591 925 63 307 167 765 65 656 10 000 6 780 10 000 2 000 2 9 042 5 000 281 04 04 251 909 251 909 34 214 10 076 26 702 11 084 5 000 2 000 2 9 042 5 000	Congo	2 665 000	1 865 500	494 358	184 890	19 774	52 402	21.752	2000	2000	3 5	2 000	25.042	000	165 221
115 020 000 80 514 000 21 336 210 7 979 743 853 448 2 261 638 938 793 10 000 74 580 10 000 2 000 29 042 5 000 8 532 000 5 972 400 1 582 686 591 925 63 307 167 765 65 686 10 000 6 780 10 000 2 000 29 042 5 000 1 358 000 950 600 251 909 94 214 10 076 26 702 11 084 5 000 371 770 770 000 66 000 059 386 456 700 059 386 050 050 050 050 050 050 050 050	Côte d'Ivoire	14 733 000	10 313 100	2 732 972	1 022 131	109.319	289 695	120 254	2000	000	3 6	000 2	23 042	2 000	822 607
8 532 000 5 972 400 1 582 686 591 925 63 307 167 765 65 656 10 000 6 786 10 000 2 900 2 9 042 5 000 2ally independent country 1 358 000 950 600 251 909 94 214 10 076 26 702 11 084 5 000 371 770 270 000 66 000 0 59 386 4 66 000 0 589 386 4 66	Niceria	115 020 000	80 514 000	21 336 210	7 070 7AR	962 440	2 264 640	102 020	2000	2000	3	7 000	23 042	2 000	4 341 709
8 332 000 5 972 400 1 582 666 591 925 63 307 167 765 65 656 10 000 6 786 10 000 2 000 2 9 042 5 000 2ally independent country 1 358 000 950 600 251 909 94 214 10 076 26 702 11 084 5 000 2 260 5 000 2 9 042 5 000 371 770 770 000 66 000 059 386 466 000 1 0				2000	25.000	0000	2 201 028	25.00	000 01	74 580	10 000	2 000	29 042	2 000	33 500 454
cally independent country 1 358 000 251 909 24 214 10 076 26 702 11 084 5 000 2 260 2 000 2 9 042 5 000 9 4 94 536 34 218 956 36 29 781 9 698 421 4 021 818 270 000 371 770 270 000 66 000	Senegai	0 222 000	2 972 400	1 582 686	591 925	63 307	167 765	969 59	10 000	6 780	10 000	2 000	29 042	5 000	2 534 201
1 358 000 950 600 251 909 94 214 10 076 25 702 11 084 5 000 2 260 5 000 2 000 2 9 042 5 000	Finanically indeper	dent country	-												
91 494 536 34 218 956 3 659 781 9 698 421 4 021 818 270 000 371 770 270 000 65 000 058 386 456 000	Gabon	1 358 000	950 600	251 909	94 214	10 076	26 702	11 084	5 000	2 260	5 000	000 6	20 07		2000
	TOTAL			91 494 536	1			4 021 818	290 000	371 770	000 020	200 33		_	77.

Page 1

Cost of Routine Immunization - Yellow Fever (A) Vaccines

																ĺ
Countries		1996			1997		-	1998			1939			2000		
Financially	Surviving	Vaccine	Vaccino	Surviving	Vaccine	Vaccine	Surviving	Vaccine	Vaccine	Surviving	Vaccine	Vaccino	Surviving	Vaccine	Vaccino	Total Cost
Dependant	000.6	USS	USS	\$,000	ns\$	USS	000.0	ns\$	us\$	9,000	US\$	US\$	000.8	ns\$	uS\$	1
% Coverage	%09			%59			20%			75%		SARRI	90%		-	
Benin	236	37 524	3 978	240	4:340	4 382	244	45 262	4 798}	248	49 290	5 225	253	53 636	5 685	251 120
Burkina Faso	412	805 59	6 944	417	71 828	7 614	424	78 652	8 337	431	35 661	9 080	438	92 856	9 843	436 323
Burundi	255	40 545	4 298	258	44 441	4711	260	48 230	5 112	263	52 271	5 541	267	56 604	6 coo	267 752
CAR	121	19 239	2 039	123	21 187	2 245	124	23 002	2 438	126	25 043	2 655	128	27 136	2 876	127 861
Chad	242	38 478	4 079	246	42 374	4 492	251	46 561	4 935	255	50 681	5 372	260	55 120	5 843	257 934
Equatorial Guinea	15	2 385	253	15	2 584	274	15	2 783	295	16	3 180	337	16	3 392	360	15 842
Ethiopia	2 305	366 495	38 848	2 343	403 582	42 780	2 383	442 047	46 857	2 428	482 565	51 152	2 477	525 124	55 663	2 455 112
Gambia	2	6519	691	42	7 235	167	43	7 977	846	4	8 745	927	44	9 328	686	44 022
Ghana	654	103 986	11 023	299	114 891	12 173	681	126 326	13 391	694	137 933	14 621	709	150 308	15 933	700 588
Guinea	288	45 792	4 854	294	50 642	5 368	299	55 465	5 879	305	60 619	6 426	311	65 932	6869	307 964
Cuinea-Bissau	68	6 201	657	39	6718	712	04	7 420	787	40	7 950	843	41	8 692	921	40 901
Kenya	1 148	182 532	19 348	1 176	202 566	21 472	1 204	223 342	23 674	1 231	244 661	25 934	1 257	266 484	28 247	1 238 261
Libena	124	19716	2 090	126	21 704	2 301	129	23 930	2 537	132	26 235	2 781	135	28 620	3 034	132 946
Mali	451	71 709		458	78 891	8 362	466	86 443	9 163	475	94 406		484	102 608	10.876	480 067
Mauritania	8	12 879	1 365	32	14 125	1 497	84	15 582	1 652	85	16 894	1 791	28	18 444	1 955	86 183
Niger	915	66 144	7 011	429	73 895	7 833	440	81 520	8 652	451	89 636	9 501		97 520	10 337	452 150
Rwanda	309	49 131	5 208	315	54 259	5 751	321	59 546	6312)	327	64 991	6 889	233	965 07	7 483	330 166
Sao Tome & Principe	9	954	101	9	1 034	110	9	1 113	118	9	1 193	126		1 272	135	6 155
Sierra Leone	182	29 938		184	31 694	3 350	186	34 503	3 657	189	37 564	3 982	191	40 432	4 292	191 549
Somalia	407	64 713		411	70 795	7 504	416	77 168	8 180	423	84 071	8 912		91 584	9 708	429 494
Sudan	1018	161 862	17 157	1 039	178 968	18 971	1 061	196 816	20 862	1 084	215 445	22 837	1 107	234 684	24 877	1 092 478
Tanzania	1148			1171	201 705	21 381	1 193	221 302	23 458	1215				262 244	27 798	1 226 845
Togo	165			168	28 938	3 067	171	31 721		174	24 583			37 736	4 000	175 088
Uganda	950	Н	15 011	964	166 049	17 601	979	181 605		995				214 544	22 742	1 007 570
Zaire	1854	294 786	31 247	1 888	325 208	34 472	1 924	356 902	37 832	1 965	390 544		2 011	426 332	45 191	1 983 912
	*	:	:				-									
Anoola	067	77 910	8 258	502	86 470	9 166	514	95 347	10 107	526	104 543	11 082		113 844	12 067	528 793
Cameroon	5	659 62	8 444		88 364		525	97 388	l	537	L	11 313	549	116 388	12 337	540 311
Cape Verde	13	l	219	13	2 239		41	2 597	275	14	2 783	295		2 968	315	13 995
Congo	104	16 536	1 753	106	18 259	1 935	107	19 849	2 104	109	21 664	2 296	111	23 532	2 494	110 422
Côte d'Ivoire	635	L	10 702	649	111 790	11 850	665	123 358	13 076	682	135 548	14 368	701	148 512	15 753	686 021
Ngera	4 522	718 998	75.214	4 584	789 594	83 697	4 651	862 761	91 453	4724	938 885	99 523	4 806	1 018 872	108 000	4 788 006
Senegai	328	52 152	5 528	334	57 532	9609	340	63 070	6 685	346	89 768	7 289	353	74 835	7 933	349 891
Finanically independent country	j Sent counts		-				=			-	-	-				
Gabon	46	7 314	LJ	48	8 268	H	99	9 275		15	10 136	1 074	52	11 024	1 169	50 895
TOTAL		3 101 454	328 754		3 419 163	362 431		3 748 955	397 389		4 092 461	433 801		4 451 364	471 845	20 807 617

22-08-96

Page 1

p:\epi\vicky\YFroutine.xls

Cost of Routine Immunization - Yellow Fever (B) Operations

Countries	-	1996		,	1997	,		800	,		666			2000		-3-
Financially	Surviving	Cost of	Service	Surviving	shipped	Service	Surviving	Cost of shipped	Service	Suving Infants	Cost of shioped	Service	Surviving	cost of	Delivery	Total Cost
Dependant	\$.000	sydnge	uss			uss	8,000	syringe	uss	s.000	syringo	US\$	000.8	syringe	USS	
% Coverage	%09			%59			20%			75%			%08			
Benin	236	180	54 462	240	198	000 09	244	202	65 692	248	237	71 538	253	241	77 846	330 597
Burkina Faso	412	314	95 077	417	345	104 250	424	351	114 154	431	411	124 327	438	418	134 769	574 416
Burundi	255	195	58 846	258	213	64 500	260	215	70 000	263	251	75 865	267	255	82 154	352 494
CAR	121	92	27 923	123	102	30 750	124	103	33 385	126	120	36 346	128	122	39 385	168 327
Chad	242	185	55 846	246	203	61 500	152	208	67 577	255	243	73 558	260	248	80 000	339 568
Equatorial Guinea	15	11	3 462	15	12	3 750	\$1	12.	4 038	91	15	4 615	91	15	4 923	20 855
Ethiopia	2 305	1759	531 923	2 343	1 937	585 750	2 383	1 970	641 577	2 428	2 316	700 385	2 477	2,363	762 154	3 232 134
Gambia	41	.6	9 462	25	35	10 500	57	36	11 577	44	42	12 692	44	42	13 538	57 955
Ghana	654	667	150 923	299	551	166 750	581	563	183 346	694	662	200 192	602	929	218154	922 318
Guinea	288	220	66 462	294	243	73 500	588	247	80 500	305	291	87 981	311	297	95 692	405 432
Guinea-Bissau	39	Š	000 6	33	32	9 750	40	33	10 769	Q	38	11 538	41	39	12615	53 845
Kenya	1 148	876	264 923	1176	972	294 000	1 204	366	324 154	1231	1 174	355 096	1257	1 199	386 769	1 630 160
Liberia	124	95	28 615	126	ş	31 500	129	101	34 731	132	126	38 077	135	129	41 538	175 022
Mali	451	¥	104 077	458	379	114 500	466	385	125 462	475	453	137 019	484	462	148 923	632 004
Mauritania	81	62	18 692	82	83	20 500	8	69	22 615	35	81	24 519	87	SS	26 769	113 459
Nger	416	317	000 96	429	355	107 250	440	364	118 462	451	430	130 096	460	439	141 538	595 251
Rwanda	60c	236	71 308	315	260	78 750	321	265	86 423	327	312	94 327	333	318	102 462	434 661
Sao Tomé & Principe	9	5	1 385	9	5	1 500	9	5	1615	9	9	1 731	9	9	1 846	8 103
Sierra Leone	182	139	42 000	184	152	46 000	186	154	50 077		180		191	182		
Somalia	407	311	62 623	411	340	102 750	416	344	112 000	423	404	122 019	432	412	132 923	565 425
Sudan	1 018	111	234 923	1 039	829	259 750	1 061	877	285 654	1 084	1 034	312 692	1 107	1 056	340 615	1 438 238
Tanzania	1 148	876	264 923	1711	998	292 750	1 193	986	321 192	1 215	1 150	350 481	1 237	1 180	380 615	1 615 131
7090	165	126	38 077	168	139	42 000	171	141	46 038	174	166	50 192	178	170	54 769	231 819
Uganda	950	725	219 231	964	767	241 000	979	608	263 577	995	949	287 019	1012	596	31; 385	1 326 458
Zaire	1 854	1 415	L.	1 888	1 561	472 000	1 924	1 591	518 000	1 965	1 875	566 827	2 011	1 918	618 769	2 611 802
Partially independent countries	t countries.	,														
Angola	767	374	113 077	505	415	125 500	514	425	138 385	526	502	151 731	537	512	165 231	696 151
Cameroon	501	382	115615	513	424	128 250	\$25	434	141 346	537	512	154 904	549	524	168 923	711 315
Cape Verde	13	10	3 000	13	11	3 250	14	12	3 769	14	13	4 038	14	13	4 308	18 424
Congo	104	79	24 000	106	83	26 500	107	88	28 808	109	104	31 442	111	106	34 154	145 369
Côte d'Ivoire	635	485	146 538	649	537	162 250	999	550	179 038	682	551	196 731	701	699	215 692	903 140
Nigeria	4 522	3 451	1 043 538	4 584	3 790	1 146 000	4 651	3 845	1 252 192	4 724	4 507	1 362 692	4 806	4 585	1 478 769	6 303 371
Schegal	328	250		334	276	83 500	340	281	91 538	346	330	99 808	353	337	108 615	384 936
Finanically independent country	dent country															
Cabon	46	35	10 615	48	40	12 000	50	41	13.462	51	49	14 712	52	50	16 000	
TOTAL	-	14 887	4 425 692		16 412	4 962 500		16 710	16 710 5 441 154		19 644	5 939 712	ابييا	20 031	6 460 615	27 317 357
p:\epi\vicky\YFroutine.xls	outine.xls						P. P.	Page 1							22	22-08-96

Page 1

e:\epi\vicky\YFsur.xls

Yellow Fever Surveillance Development Costs (for 5 years in 33 countries)

		WYEARUS	A VEARZ	WYEAR	WYEAR4	XXEAR5
_	Guidelines and forms	33 900				
		56 500				
2	Awareness seminars	37 290	37 290	37 290		
8	Field staff training	24 860	24 860	24 860 24 860	24 860 24 860	24 860 24 860
38	Laboratory staff training	50 850	50 850	50 850	50 850	50 850
ဗ္ဗ	3C Consultant support to laboratories	22 600	22 600	22 600	-	
4	Specimen collection	24 860	24 860	24 860	24 860	24 860
			24 860	24 860	24 860	24 860
ည	Reagents	56 500	56 500	56 500	56 500	56 500
	Lotals by year	098-208-3-3	241,820	291,540	123.1650	第27550

World Health Organization

ANNEX ONE

Extract from the Plan for Vaccine preventable diseases in the African Region. WHO, regional Office for Africa, Brazzaville

YELLOW FEVER CONTROL

From 1987 to 1991, a total of 18 735 cases of yellow fever were reported from Member States in the African Region. This represent the greatest amount of yellow fever activity reported to WHO for any 5-year period since reporting began in 1948. Almost all the increase in yellow fever activity is reported from the African Region. Fewer cases were reported in 1992 (295 cases) and in 1993 (393 cases). In 1994, there was another resurgence of yellow fever in Africa with outbreaks reported in West Africa (Ghana, Nigeria), Central Africa (Gabon) and East Africa (Kenya).

Since 1965, outbreaks have been reported in Angola (1988), Burkina Faso (1969, 1983, 1984, 1985), Cameroon (1990), Gambia (1978, 1979), Ghana (1977-79, 1983, 1993-1994), Côte d'Ivoire (1979, 1982), Mali (1987), Nigeria (1974, 1979, 1986-1991), Senegal (1965), Sierra Leone (1975), and Togo (1987). In 1993, an outbreak of yellow fever was reported for the first time since 1943 in Kenya with 54 patients meeting the case definition and 28 deaths (VFR 52%). Difficulties encountered in obtaining laboratory confirmation of the outbreak in Kenya underscored the need for improved surveillance and laboratory diagnostic capabilities for yellow fever in the African Region. In 1994, the first outbreak ever documented in Gabon occurred from November 1994 to January 1995 in the North East Region of the country. Some 30 cases were reported.

Outbreak investigations have shown that a high percentage of cases are now occurring among children. For example, during the yellow fever outbreak in Ghana during 1993-1994, 27% (28/103) reported cases were under 5 years of age, and 18% (19/103) were 5 to 14 years of age. In 1991, the Ministry of Health in Nigeria reported 25% (568/2229) of all yellow fever cases under 5 years of age and 29% (641/2229) between 5 and 14 years of age.

WHO has identified 33 countries in the African Region currently at risk for yellow fever epidemics. In 1998, the joint WHO/UNICEF Technical Group on Immunization in Africa recommended that yellow fever immunization be integrated into immunization programmes in all 33 countries. However, financing yellow fever vaccine is a major obstacle to its procurement. Although 17 countries adopted the policy, only 13 (Angola, Burkina Faso, Central African Republic, Chad, Côte d'Ivoire, Gabon, Gambia, Ghana, Mali, Mauritania, Niger, Senegal and Togo) were able to obtain funds to finance and procure the vaccine. Annex two shows the costs of integrating yellow fever vaccine into routine immunization services. To date, reports of yellow fever epidemics in countries without routine immunization against yellow fever have managed to mobilize the enormous resources required to conduct emergency immunization campaigns. However, these outbreak control measures disrupt health services and strain donor resources as well as health workers.

Since 1994 training course on polio diagnostic techniques and vaccine potency testing held at the Nogochi Memorial Institute for Medical Research for eight countries (The Gambia, Ghana, Kenya, Nigeria, Tanzania, Uganda, Zaīre, Zimbabwe) also included training on yellow fever vaccine potency testing, and the IgM assay for yellow fever diagnosis. A workshop on yellow fever laboratory diagnosis was also conducted in June 1995 at Kemri, in Kenya. Following the training, it is important to ensure the supply of laboratories with necessary equipment and supplies. Training/refresher courses are also needed for pathologists in the African Region to improve diagnostic capabilities based on histopathology. Improved surveillance for yellow fever in countries at risk is also necessary for early identification of outbreaks.

World Health Organization

Extract from the Plan for Vaccine preventable diseases in the African Region. WHO, regional Office for Africa, Brazzaville

SURVEILLANCE OF TARGET DISEASES

In September 1992, a surveillance system was introduced in the Region for the reporting of the EPI target diseases. The system aims to encourage high quality surveillance and data utilization at the country level. EPI/AFRO currently produces a quarterly EPI bulletin with feedback information to encourage Member States to improve completeness and timeliness of reporting, analyze their data and use the data for action. Approximately 38 (87%) of the countries in the Region can provide monthly surveillance data on vaccine-preventable diseases to the Regional Office.

Completeness and timeliness of reporting must improve in all Member States if data are to be useful for disease control. The assessments of disease surveillance and control conducted during 1992 to 1994 in Botswana, Kenya, Lesotho, Malawi, Swaziland, Tanzania, Rwanda and Zimbabwe indicated a need to introduce standard case definitions, and to train and mobilize provincial and district level staff to investigate all cases of NNT and acute flaccid paralysis, and outbreaks of nieasles. The introduction of standard performance indicators is also necessary to monitor the quality of surveillance and stimulate its improvement at national, provincial and district levels.

MEASLES CONTROL

The regional objectives for measles control require:

- 90% reduction in measles incidence in every country compared to pre-immunization levels by
 1995, and
- 95% reduction in measles mortality in every country compared to pre-immunization levels.

POLIOMYELITIS ERADICATION

The regional objectives for polio eradication require that, by the year 2000:

- there will be no cases of clinical poliomyelitis associated with wild poliovirus,
- there will be no wild poliovirus identified anywhere in the Region, through virological sampling
 of AFP cases, contacts and possibly waste water,
- the process of independent certification of polio free status will be initiated at the national level, leading to full regional certification.

HEPATITIS B CONTROL

The regional objective for Hepatitis B control requires:

- introduction of Hepatitis B vaccine into the childhood immunization programme of all Member States by 1997,
- attainment of at least 70% regional coverage by one year of age with three doses of IIB vaccine by the Year 2000.

YELLOW FEVER CONTROL

The regional objective for yellow fever control requires:

- Introduction of yellow fever vaccine into the childhood immunization programme in all 33 countries at risk by 1997,
- attainment of at least 80% coverage with yellow fever vaccine in children under 5 years of age in all 33 countries at risk by the Year 2000.

Global Programme for Vaccines and Immunization

World Health Organization

Extract from the Plan for Vaccine preventable diseases in the African Region. WIO, regional Office for Africa, Brazzaville

IMPROVING DISEASE CONTROL

Immunization Activities

The Regional Office will promote and support the implementation of effective immunization strategies, both routine and supplemental, to achieve the eradication of poliomyelitis, elimination of neonatal tetanus, and control of measles and yellow fever.

National immunization programmes will implement the necessary strategies to achieve and sustain in each district at least 80% coverage by one year of age for all scheduled childhood vaccines.

National health authorities will plan and conduct the necessary supplemental immunization activities and targeted approaches to achieve the EPI disease reduction/eradication targets.

Disease surveillance and response

The Regional Office will strengthen the regional EPI surveillance system to encourage timely and complete reporting of EPI priority diseases and monitoring of standard performance indicators. The Regional Office will regularly provide feedback information through visits as other forms of communication including the EPI bulletin.

National health authorities will need to increase the efficiency of the disease surveillance systems, particularly at the district level by improving the completeness and timeliness of reporting of AFP, NNT and measles among the priority communicable diseases. National health authorities will need to implement obligatory immediate reporting and response for all cases of AFP.

National health authorities will provide appropriate training and mobilization of national, provincial and district level staff to investigate every case of suspected AFP and neonatal tetanus as well as every outbreak of measles. They will also ensure prompt and appropriate outbreak response immunization.

National health authorities will strive to collect two fecal specimens from every reported AFP case and ensure the transport of specimens via a reverse cold chain to a WHO-designated national polio-laboratory.

National health authorities will establish a system for regular feedback of EPI-related surveillance data to reporting units.

ANNEX TWO

Extract from the Plan for Vaccine preventable diseases in the African Region. WHO, regional Office for Africa, Brazzaville

Cost of introducing yellow fever vaccine into routine childhood immunization services

Assumptions

1. The following countries at risk will incorporate yellow fever into their schedule:

In 1996:

Island Nations at risk: Cape Verde, Sao Tome & Principe Central Block Countries at risk: Cameroon, Congo, Equatorial Guinea Western Block Countries at risk: Benin, Guinea, Guinea Bissau, Liberia, Sierra Leone

In 1997:

Eastern Block Countries at risk: Burundi, Eritrea, Kenya, Rwanda, Tanzania, Uganda

In 1998:

Countries in difficult circumstances at risk: Ethiopia, Nigeria, Zaîre

Note: the following countries at risk have already procured yellow fever vaccine and incorporated into their schedule: Angola, Burkina Faso, CAR, Côte d'Ivoire, Gabon, Gambia, Ghana, Mali, Mauritania, Niger, Senegal, Togo.

- Measles coverage is based on data reported to WHO as of August 1994.
- 3. The number of yellow fever vaccine doses is calculated using the estimated size of the 1993 surviving infant population, a population growth rate of 3.2%, the established "start date", the 1993 measles immunization coverage level as an approximate baseline for yellow fever immunization coverage, and increasing annual coverage.
- 4. The vaccine wastage rate is 40% which is equivalent to a wastage factor of 1.66.
- 5. The cost of freight is calculated as 10% of vaccine costs.
- 6. The analysis covers all 33 countries at risk in the WHO African Region.
- 7. Costs have been divided in four categories:
 - Vaccine
 - Syringe/needles
 - freight
 - incremental service delivery costs
- 8. Incremental service delivery costs are the small amount of additional resources required to add yellow fever vaccine to the existing childhood immunization programme. The costs include additional supervision, social mobilization and labor. They are roughly estimated to be \$0.38 in addition to the \$15 per fully immunized child (see table 1).
- 9. I dose of yellow fever vaccine (10 dose vial) = \$0.25 I syringe/needle and fraction of the sterilizer = \$0.05

Based on the Plan for Vaccine preventable diseases in the African Region WHO, Regional Office for Africa, Brazzaville

INTRODUCTION OF YELLOW FEVER VACCINE INTO THE CHILDHOOD IMMUNIZATION PROGRAMMES OF 33 COUNTRIES AT RISK

Countries	Target Pop.	Measies	Start		coverage				
	1993 **	coverage ***	Date	1995	1998	1997	1998	1999	2000
	(millions)			reported			projected		
Angola *	0.4501	47	1994	30	60	65	70	75	80
Benin	0.2215	66	1998		70	74	78	80	83
 Burkina Faso*	0.3951	41	1994	45	55	63	70	75	80
Burundi	0.2422	67	1997			67	72	77	80
Cameroon	0.4672	33	1996		45	50	60	70	60
Cape Verde	0.0133	95	1996	1 .	95	95	95	95	95
CAR*	0.1274	55	1994	36	60	65	70	75	80
Ched*	0.2267	25	1994	28	35	45	60	70	80
Congo	0.0979	47	1996	ŀ	54	60	67	75	60
Côle d'Ivoire*	0.5905	52	1994	38	64	68	72	76	80
Equat. Guinea	0.0143	70	1996			72	76	78	80
Ethiopia	2.3067	22	1998]			65	75	80
Gabon*	0.0476	65	1994	23	70	75	80	82	85
Gambia*	0.035	66	1994	87	90	90	90	90	95
Ghana*	0.6163	50	1994	22	60	67	72	75	80
Guinea	0.2708	56	1995		56	60	66	72	80
Guinea Bissau	0.0372	52	1995		55	63	70	75	80
Kenva	1.0373	40	1997			55	65	75	80
Liberia	0.1149	40	1995		45	60	65	72	80
Malı*	0.4236	51	1994	3	63	67	72	77	80
Mauritenia *	0.088	49	1994	55	55	63	70	74	80
Niger*	0.3751	18	1994	17	40	50	60	70	80
Nigeria	4.738	34	1998	1	50	65	72	77	80
Rwanda	0.3523	81	1997	25	35	45	55	89	90
Sao Tome	0.005	69	1996	2	75	80	85	89	90
Senegal*	0,3076	46	1994	46	60	65	70	75	80
Sierra Leone	0.1823	67	1996		70	73	75	77	80
Somelie	0.407	30					50	70	60
Sudan	1.018	74					50	70	80
Togo*	0.1548	47	1994	14	55	65	70	75	80
Tenzenia	1.213	77	1997	1		85	80	83	85
Uganda	0.8605	68	1997	1		73	75	77	80
Zeīre	1.7346	17	1998	8			65	73	80
Coverage with	yellow fever va	l ccine	l	50%	59%	67%	72%	78%	83%
	countries recei]		17	24	29	33	33	33

^{**} Target populations is Surviving Infants = Pop. x CBR x (1 - IMR)

^{*** 1993} measles coverage based on data reported to WHO as of &94

WORLD HEALTH ORGANIZATION

Extract from the Plan for Vaccine preventable diseases in the African Region WHO, Regional Office for Africa, Brazzaville

INTRODUCTION OF YELLOW FEVER VACCINE INTO THE CHILDHOOD IMMUNIZATION PROGRAMMES OF 33 COUNTRIES AT RISK

COUNTRIES	1995	# Surviving Infa 1996	nts immunized 1997	with YF Vaccin	re (000) 1999	2000	Total
Angola	232	288	322	357	395	435	2 029
Benin	0	165	180	196	207	222	970
Burkina Faso	184	232	274	315	348	383	1 730
Burundi	704	232	178	198	218	234	820
Cameroon	0	224	257	318	383	452	1 63
Cameroon Capa Verde	0	13	14	14	15	15	7
Capa verse CAR	72	81	91	101	112	123	58
Chad	70	85	112	154	186	219	82
Congo	0	56	65	74	86	95	37
Côte d'Ivoire	366	402	441	482	525	571	2 78
	0	0	11	12	13	14	5
Equal. Guinea	0	ا ا	6	1 071	2 025	2 229	5 32
Ethiopia Gabon	32	35	39	43	46	49	24
Gabon Gambia	32 24	26	29	31	33	35	17
Gambia Ghada	337	394	454	503	511	596	2 82
		162	179	203	228	262	1 03
Guinea	0	22	26	30	33	36	14
Guinea Bissau	0	22	627	765	911	1 002	3 30
Kenya	0	55	76	85	97	111	42
Liberia Mali	240	284	312	346	382	409	1 97
	47	52	61	70	76	85	39
Mauritania Niger	97	160	206	255	307	363	1 38
	2 445	3 028	3 385	3 869	4 271	4 579	21 57
Nigeria Rwanda	91	131	174	220	367	383	1 36
Seo Tome	0	'4	"4	5	5	5	2
Senegal	171	197	220	244	270	297	1 39
Sierra Leona	0		146	155	164	176	77
Sierra Ceone Somalia	U	1 1301	1401	no dela a			.,
Sudan				no dela a			
Togo	80	91	111	123	136	150	69
Tanzania	0	"	1 133	1 101	1 179	1 246	4 65
	0		690	732	776	832	3 03
Uganda Zaíre	o	ő	000	1 279	1 482	1 676	4 43
No Infants	4 488	6 323	9 817	13 351	15 817	17 284	67 08
Coverage	50%	59%	67%	72%	78%	83%	
Cost x \$ 1000	1995	1996	1997	1998	1999	2000	1995-2000
Vaccine	1 870	2 634	4 091	5 826	6 590	7 201	28 21.
Syr/needle	229	322	501	713	807	881	3 45
Freight	187	263	409	583	659	720	2 82
Serv. Del.	1 706	2 402	3 731	5 313	6 010	6 568	25 73
TOTAL US\$	3 992	5 621	8 732	12 435	14 066	15 370	60 21

This lotal (60 216) excludes surveillance and operation costs



